CA2640366A1 - Method for treatment of neuropathic pain - Google Patents
Method for treatment of neuropathic pain Download PDFInfo
- Publication number
- CA2640366A1 CA2640366A1 CA002640366A CA2640366A CA2640366A1 CA 2640366 A1 CA2640366 A1 CA 2640366A1 CA 002640366 A CA002640366 A CA 002640366A CA 2640366 A CA2640366 A CA 2640366A CA 2640366 A1 CA2640366 A1 CA 2640366A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- substituted
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 15
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- -1 hydroxy- Chemical group 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 229910019142 PO4 Inorganic materials 0.000 claims description 12
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 239000010452 phosphate Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 150000002367 halogens Chemical group 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Chemical group 0.000 claims description 4
- 229910052801 chlorine Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000001743 benzylic group Chemical group 0.000 claims description 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- YYQGUWHFXVXQOO-GFCCVEGCSA-N 2-chloro-4-[[3-[(2R)-2-hydroxybutyl]-1-methyl-2-oxobenzimidazol-5-yl]amino]pyridine-3-carbonitrile Chemical compound ClC1=C(C#N)C(=CC=N1)NC1=CC2=C(N(C(N2C[C@@H](CC)O)=O)C)C=C1 YYQGUWHFXVXQOO-GFCCVEGCSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 150000002978 peroxides Chemical class 0.000 claims description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 1
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 21
- 108020003175 receptors Proteins 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 13
- 208000002193 Pain Diseases 0.000 abstract description 8
- 230000036407 pain Effects 0.000 abstract description 8
- 230000008859 change Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 22
- 150000001412 amines Chemical class 0.000 description 20
- 239000008194 pharmaceutical composition Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003937 drug carrier Substances 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- HSQYFABUCFBTMX-UHFFFAOYSA-N 3-(4-iodophenyl)cyclopentan-1-one Chemical compound C1=CC(I)=CC=C1C1CC(=O)CC1 HSQYFABUCFBTMX-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 6
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 208000028389 Nerve injury Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 125000003107 substituted aryl group Chemical group 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 101150041968 CDC13 gene Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229940051866 mouthwash Drugs 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- OQYSTACFXILNOF-UHFFFAOYSA-N 1-amino-3-(4-octylphenyl)cyclopentane-1-carbonitrile Chemical compound C1=CC(CCCCCCCC)=CC=C1C1CC(N)(C#N)CC1 OQYSTACFXILNOF-UHFFFAOYSA-N 0.000 description 3
- ORWUBGMKMYZJFF-UHFFFAOYSA-N 3-(4-oct-1-ynylphenyl)cyclopentan-1-one Chemical compound C1=CC(C#CCCCCCC)=CC=C1C1CC(=O)CC1 ORWUBGMKMYZJFF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 3
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- BLASFTPNKGQBNF-UHFFFAOYSA-N [1-amino-3-(4-octylphenyl)cyclopentyl]methanol Chemical compound C1=CC(CCCCCCCC)=CC=C1C1CC(N)(CO)CC1 BLASFTPNKGQBNF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 206010053552 allodynia Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010039670 Sciatic nerve injury Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WVBOASXXEYCGQG-UHFFFAOYSA-N [1-amino-3-(4-octylphenyl)cyclopentyl]methyl dihydrogen phosphate Chemical compound C1=CC(CCCCCCCC)=CC=C1C1CC(N)(COP(O)(O)=O)CC1 WVBOASXXEYCGQG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000009762 endothelial cell differentiation Effects 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006313 (C5-C8) alkyl group Chemical group 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- VLBVSHQBIHNIKD-UHFFFAOYSA-N 1-amino-3-(4-octylphenyl)cyclopentane-1-carboxylic acid Chemical compound C1=CC(CCCCCCCC)=CC=C1C1CC(N)(C(O)=O)CC1 VLBVSHQBIHNIKD-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- GAILOZLACZOIAZ-UHFFFAOYSA-N 3-(4-octylphenyl)cyclopentan-1-one Chemical compound C1=CC(CCCCCCCC)=CC=C1C1CC(=O)CC1 GAILOZLACZOIAZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- 102000036530 EDG receptors Human genes 0.000 description 1
- 108091007263 EDG receptors Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000926140 Homo sapiens Gem-associated protein 2 Proteins 0.000 description 1
- 101001038001 Homo sapiens Lysophosphatidic acid receptor 2 Proteins 0.000 description 1
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
- 101001021281 Homo sapiens Protein HEXIM1 Proteins 0.000 description 1
- 101000716750 Homo sapiens Protein SCAF11 Proteins 0.000 description 1
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 1
- 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 1
- 101000653757 Homo sapiens Sphingosine 1-phosphate receptor 4 Proteins 0.000 description 1
- 101000651197 Homo sapiens Sphingosine kinase 2 Proteins 0.000 description 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100040387 Lysophosphatidic acid receptor 2 Human genes 0.000 description 1
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100020876 Protein SCAF11 Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 1
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 description 1
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 1
- 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 1
- 102100029803 Sphingosine 1-phosphate receptor 4 Human genes 0.000 description 1
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- 102100027662 Sphingosine kinase 2 Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- FAPDDOBMIUGHIN-UHFFFAOYSA-K antimony trichloride Chemical compound Cl[Sb](Cl)Cl FAPDDOBMIUGHIN-UHFFFAOYSA-K 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- JFIOVJDNOJYLKP-UHFFFAOYSA-N bithionol Chemical compound OC1=C(Cl)C=C(Cl)C=C1SC1=CC(Cl)=CC(Cl)=C1O JFIOVJDNOJYLKP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- PGUYAANYCROBRT-UHFFFAOYSA-N dihydroxy-selanyl-selanylidene-lambda5-phosphane Chemical compound OP(O)([SeH])=[Se] PGUYAANYCROBRT-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000026721 endothelial cell chemotaxis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- UMIPWJGWASORKV-UHFFFAOYSA-N oct-1-yne Chemical compound CCCCCCC#C UMIPWJGWASORKV-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- RUUFMHUAHUPZSS-UHFFFAOYSA-N oxido-oxo-sulfinophosphanium Chemical class P(=O)(=O)S(=O)O RUUFMHUAHUPZSS-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JRPHGDYSKGJTKZ-UHFFFAOYSA-K selenophosphate Chemical compound [O-]P([O-])([O-])=[Se] JRPHGDYSKGJTKZ-UHFFFAOYSA-K 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 150000003409 sphingosine 1-phosphates Chemical class 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
Compounds and methods useful for preventing and treating pain,e.g., neuropathic pain, in a subject in need thereof are provided. The compounds can be "SlP modulating" agents that are capable of inducing a detectable change in SlP receptor activity.
Description
METHOD FOR TREATMENT OF NEUROPATHIC PAIN
Cross-Reference to Related Applications [0001] This application claims priority to Provisional Application Nos.
60/762,589, filed January 27, 2006, the disclosure of which is incorporated by reference in its entirety.
US Government Rights .10 [0002] This invention was made with United States Government support under Grant No. RO1 GM067958 awarded by the National Institutes of Health. The United States Government has certain rights in the invention.
Field of the Invention [0003] The present invention relates to sphingosine 1-phosphate analogs, with activity at one or more sphingosine 1-phosphate receptors, which are useful for preventing and treating neuropathic pain.
Background [0004] Sphingosine-l-phosphate (SIP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family. The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (G,,,) subunits and beta-gamma'(GRy) dimers.
[0005] Sphingosine-l-phosphate (S 1P) has been demonstrated to induce cellular processes, including those that result in platelet aggregation, cell proliferation, cell morphology, tumor-cell invasion, endothelial cell chemotaxis and endothelial cell in vitro angiogenesis. Tlierefore, S1P receptors have been targets for thefapy of, for example, wound healing and tumor growth inhibition. Sphingosine-l-phosphate is believed to signal cells in part via a set of G protein-coupled receptors named SIP1, S 1 P2, S 1P3, S 1P4, and S 1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDGB, respectively). These receptors share 50-55% identical amino acids and cluster with three other receptors (LPAI, LPA2, and LPA3 (formerly EDG2, EDG4 and EDG7, respectively) for the structurally related lysophosphatidic acid (LPA).
[0006] S 1P receptors have been selected as drug targets because the individual receptors are both tissue and response specific. Tissue specificity of the S 1 P receptors is desirable because development of an agonist or antagonist selective for one receptor localizes the cellular response to tissues containing that receptor, limiting unwanted side effects. Response specificity of the S 1P receptors is also of importance because it allows for the development of agonists or antagonists that can initiate or suppress certain cellular responses without affecting other responses. For example, the response specificity of the S 1P receptors could allow for an S 1P mimetic that initiates =
platelet aggregation without affecting cell morphology.
[0007] Pain can be nociceptive or neuropathic in nature. Neuropathic pain is characterized by its chronic nature, an absence of an obvious direct cause (e.g., tissue damage), hyperalgesia, or allodynia. Hyperalgesia is an exaggerated response to a painful stimulus. Allodynia is the perception of normal stimuli as painful (examples include the touch of clothing, warrn or cool air, etc.). Neuropathic pain can be a sequel to nerve damage in an extremity such as an arm, or more often, a leg.
Precipitating events can include trauma, e.g., motor vehicle accidents or amputations (e.g., phantom limb pain)_ Neuropathic pain can occur due to an adverse effect of drug therapies, e.g., vincristine or paclitaxel (Taxo1TM), or can occur as a component of disease pathologies, such as diabetes type 1 or type 2, shingles, HIV-1 infections, etc.
Typically, neuropathic pain does not respond to opiates or =non-steroidal anti-inflammatory drugs such as aspirin. Treatment of neuropathic pain is an important unmet medical need and this invention addresses that need.
[0008] There is a long felt need in the art for compounds and methods which are useful for preventing and treating pain. The present invention satisfies these needs.
Cross-Reference to Related Applications [0001] This application claims priority to Provisional Application Nos.
60/762,589, filed January 27, 2006, the disclosure of which is incorporated by reference in its entirety.
US Government Rights .10 [0002] This invention was made with United States Government support under Grant No. RO1 GM067958 awarded by the National Institutes of Health. The United States Government has certain rights in the invention.
Field of the Invention [0003] The present invention relates to sphingosine 1-phosphate analogs, with activity at one or more sphingosine 1-phosphate receptors, which are useful for preventing and treating neuropathic pain.
Background [0004] Sphingosine-l-phosphate (SIP) is a lysophospholipid mediator that evokes a variety of cellular responses by stimulation of five members of the endothelial cell differentiation gene (EDG) receptor family. The EDG receptors are G-protein coupled receptors (GPCRs) and on stimulation propagate second messenger signals via activation of heterotrimeric G-protein alpha (G,,,) subunits and beta-gamma'(GRy) dimers.
[0005] Sphingosine-l-phosphate (S 1P) has been demonstrated to induce cellular processes, including those that result in platelet aggregation, cell proliferation, cell morphology, tumor-cell invasion, endothelial cell chemotaxis and endothelial cell in vitro angiogenesis. Tlierefore, S1P receptors have been targets for thefapy of, for example, wound healing and tumor growth inhibition. Sphingosine-l-phosphate is believed to signal cells in part via a set of G protein-coupled receptors named SIP1, S 1 P2, S 1P3, S 1P4, and S 1P5 (formerly EDG1, EDG5, EDG3, EDG6 and EDGB, respectively). These receptors share 50-55% identical amino acids and cluster with three other receptors (LPAI, LPA2, and LPA3 (formerly EDG2, EDG4 and EDG7, respectively) for the structurally related lysophosphatidic acid (LPA).
[0006] S 1P receptors have been selected as drug targets because the individual receptors are both tissue and response specific. Tissue specificity of the S 1 P receptors is desirable because development of an agonist or antagonist selective for one receptor localizes the cellular response to tissues containing that receptor, limiting unwanted side effects. Response specificity of the S 1P receptors is also of importance because it allows for the development of agonists or antagonists that can initiate or suppress certain cellular responses without affecting other responses. For example, the response specificity of the S 1P receptors could allow for an S 1P mimetic that initiates =
platelet aggregation without affecting cell morphology.
[0007] Pain can be nociceptive or neuropathic in nature. Neuropathic pain is characterized by its chronic nature, an absence of an obvious direct cause (e.g., tissue damage), hyperalgesia, or allodynia. Hyperalgesia is an exaggerated response to a painful stimulus. Allodynia is the perception of normal stimuli as painful (examples include the touch of clothing, warrn or cool air, etc.). Neuropathic pain can be a sequel to nerve damage in an extremity such as an arm, or more often, a leg.
Precipitating events can include trauma, e.g., motor vehicle accidents or amputations (e.g., phantom limb pain)_ Neuropathic pain can occur due to an adverse effect of drug therapies, e.g., vincristine or paclitaxel (Taxo1TM), or can occur as a component of disease pathologies, such as diabetes type 1 or type 2, shingles, HIV-1 infections, etc.
Typically, neuropathic pain does not respond to opiates or =non-steroidal anti-inflammatory drugs such as aspirin. Treatment of neuropathic pain is an important unmet medical need and this invention addresses that need.
[0008] There is a long felt need in the art for compounds and methods which are useful for preventing and treating pain. The present invention satisfies these needs.
Summary [0009] The present invention provides, in one aspect, compounds and methods useful for preventing and treating pain in a subject in need thereof. The method includes administering to said subject an effective amount of a compound having formula (I) or formula (II):
R /
PZD-, C~ ~
6._. R
R---R7 X or (CH2)n X
I II
wherein Wand R7 are independently CH, or CH2, R5 is C, CH, or N, R6 is CH, CH2, 0, S or NR3, R3 is hydrogen, or an alkyl group.
[0010] X is selected from hydroxyl (-OH), phosphate (-OP03H2), phosphonate (-CH2PO3H2), alpha-substituted phosphonate, R' is selected from the group consisting of hydrogen, halo, tri-fluoromethyl, (Q-Clo)-alkyl, (CI-Clo) alkyl substituted with halo, hydroxy, alkoxy, or cyano, R2 is selected from the group consisting of (Ci-CZC)alkyl, cycloalkyl substituted alkyl, (C2-C2O)alkenyl, (C2-Cao)alkynyl, aryl, alkyl substituted aryl, arylalkyl, and aryl substituted arylalkyl, wherein one or more of the carbon atoms in the R2groups can be independently replaced with non-peroxide oxygen, sulfur or NR8, wherein R8 is hydrogen, or an (Ct-CIo) alkyl group, wherein the alkyl, alkenyl, and alkynyl groups in R2 are optionally substituted with oxo, n is 0, 1, 2 or 3, and ~`--' represents 1, 2, or 3, optional double bonds,, or a pharmaceutically 20, acceptable salt or ester thereof.
[0011] In another aspect, the present invention provides for the use of a compound of formula (I), formula (II), or a pharmaceutically acceptable salt thereof to prepare a medicament for preventing and treating pain in a mammal (e.g., a human).
Brief Description of the Drawings -[0012] FIG. 1 is an illustration of a synthetic route' to prepare compoiznds used' in` ' the disclosed method.
R /
PZD-, C~ ~
6._. R
R---R7 X or (CH2)n X
I II
wherein Wand R7 are independently CH, or CH2, R5 is C, CH, or N, R6 is CH, CH2, 0, S or NR3, R3 is hydrogen, or an alkyl group.
[0010] X is selected from hydroxyl (-OH), phosphate (-OP03H2), phosphonate (-CH2PO3H2), alpha-substituted phosphonate, R' is selected from the group consisting of hydrogen, halo, tri-fluoromethyl, (Q-Clo)-alkyl, (CI-Clo) alkyl substituted with halo, hydroxy, alkoxy, or cyano, R2 is selected from the group consisting of (Ci-CZC)alkyl, cycloalkyl substituted alkyl, (C2-C2O)alkenyl, (C2-Cao)alkynyl, aryl, alkyl substituted aryl, arylalkyl, and aryl substituted arylalkyl, wherein one or more of the carbon atoms in the R2groups can be independently replaced with non-peroxide oxygen, sulfur or NR8, wherein R8 is hydrogen, or an (Ct-CIo) alkyl group, wherein the alkyl, alkenyl, and alkynyl groups in R2 are optionally substituted with oxo, n is 0, 1, 2 or 3, and ~`--' represents 1, 2, or 3, optional double bonds,, or a pharmaceutically 20, acceptable salt or ester thereof.
[0011] In another aspect, the present invention provides for the use of a compound of formula (I), formula (II), or a pharmaceutically acceptable salt thereof to prepare a medicament for preventing and treating pain in a mammal (e.g., a human).
Brief Description of the Drawings -[0012] FIG. 1 is an illustration of a synthetic route' to prepare compoiznds used' in` ' the disclosed method.
[0013] FIG. 2 is an illustration of a synthetic route to prepare the compound VPC01091-C.
[0014] FIG. 3 is a graphical representation of the results from administration of a compound of formula VPC01091.
[0015] FIG. 4 is a graphical representation of the results from administration of a vehicle control.
[0016] FIG. 5 is a graphical representation of the results from a sciatic nerve injury preclinical model of neuropathic pain.
Detailed Description [0017] The following abbreviations are used herein: S 1P, sphingosine-l-phosphate; GPCR, G-protein coupled receptor; SAR, structure-activity relationship;
EDG, endothelial cell differentiation gene; EAE, experimental autoimmune encephalomyelitis; NOD non-obese diabetic; TNFoc, tumor necrosis factor alpha;
HDL, high density lipoprotein; and RT-PCR, reverse transciptase polymerase chain reaction [0018] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing, the preferred methods and materials are described herein. The following terms have the meaning associated with it in this section.
[0019] The articles "a" and "an" are used herein to refer to one or to more'than one (e.g., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0020) The term "affected cell" refers to a cell of a subject afflicted with a disease or disorder, which affected cell has an altered phenotype relative to a subject not afflicted with a disease or disorder. Cells or tissue are "affected" by a disease or disorder if the cells or tissue have an altered phenotype relative to the same cells or tissue in a subject not afflicted with a disease or disorder.
[0014] FIG. 3 is a graphical representation of the results from administration of a compound of formula VPC01091.
[0015] FIG. 4 is a graphical representation of the results from administration of a vehicle control.
[0016] FIG. 5 is a graphical representation of the results from a sciatic nerve injury preclinical model of neuropathic pain.
Detailed Description [0017] The following abbreviations are used herein: S 1P, sphingosine-l-phosphate; GPCR, G-protein coupled receptor; SAR, structure-activity relationship;
EDG, endothelial cell differentiation gene; EAE, experimental autoimmune encephalomyelitis; NOD non-obese diabetic; TNFoc, tumor necrosis factor alpha;
HDL, high density lipoprotein; and RT-PCR, reverse transciptase polymerase chain reaction [0018] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing, the preferred methods and materials are described herein. The following terms have the meaning associated with it in this section.
[0019] The articles "a" and "an" are used herein to refer to one or to more'than one (e.g., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0020) The term "affected cell" refers to a cell of a subject afflicted with a disease or disorder, which affected cell has an altered phenotype relative to a subject not afflicted with a disease or disorder. Cells or tissue are "affected" by a disease or disorder if the cells or tissue have an altered phenotype relative to the same cells or tissue in a subject not afflicted with a disease or disorder.
[0021] A disease or disorder is "alleviated" if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is reduced.
[0022] An" analog" of a chemical compound is a compound that, by way of example, resembles another in structure but is not necessarily an isomer (e.g., 5-fluorouracil is an analog of thymine).
[0023] The terms "cell," "cell line," and "cell culture" may be used interchangeably. A "test" cell, tissue, sample, or subject is one being examined or treated. A "control" cell, tissue, sample, or subject is a cell, tissue, sample, or subject of the same type as a test cell, tissue, sample, or subject. The control may, for example, be examined at precisely or nearly the same time the test cell, tissue, sample, or subject is examined. The control may also, for example, be examined at a time distant from the time at which the test cell, tissue, sample, or subject is examined, and the results of the examination of the control may be recorded so that the recorded results may be compared with results obtained by examination of a test cell, tissue, sample, or subject. The control may also be obtained from another source or similar source other than the test group or a test subject, where the test sample is obtained from a subject suspected of having a disease or disorder for which the test is being performed.
[0024] A "pathoindicative" cell, tissue, or sample is one which, when present, is an indication that the animal in which the cell, tissue, or sample is located (or from which the tissue was obtained) is afflicted with a disease or disorder. For example, the presence of one or more breast cells in a lung tissue of an animal is an indication that the.animal is afflicted with metastatic breast cancer.
[0025] A tissue "normally comprises" a cell -if one or more of the cell are present in the tissue in an animal not afflicted with a disease or disorder.
[0026] The word "detect" and its grammatical variants refer to measurement of the species without quantification. The terms "detect" and "identify"- are used interchangeably herein. The words "determine" or "measure" and their grammatical variants refer to measurement of the species with quantification. The terms "determine" or "measure" are used interchangeably herein.
[0027] A "detectable marker" or a` reporter molecule" is an atom or a molecule that permits the specific detection of a compound comprising the marker in the presence of similar compounds without a marker. Examples of detectable markers or reporter molecules include, e.g., radioactive isotopes, antigenic determinants, enzymes, nucleic acids available for hybridization, chromophores, fluorophores, chemiluminescent molecules, electrochemically detectable molecules, and molecules that provide for altered fluorescence-polarization or altered light-scattering.
[0028] A"disease ' is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate. In contrast, a "disorder" in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
[0029] The term "effective amount" means an amount sufficient to produce a selected effect. For example, an effective amount of an S 1P receptor antagonist is an amount that decreases the cell signaling activity of the S 1 P receptor.
[0030] A "functional" molecule is a molecule in a form in which it exhibits a property by which it is characterized. For example, a functional enzyme is one which exhibits the catalytic activity by which the enzyme is characterized.
[0031] The term "inhibit" refers to the ability of a compound to reduce or impede a described function. Preferably, inhibition is by at least 10%, more preferably by at least 25%, even more preferably by at least 50%; and most preferably, the function is inhibited by at least 75%.
[0032] The term "instructional material" includes a publication, a recording;
a diagram, or any other medium of expression, which can be used to comrnunicate the usefulness, in the kit for effecting alleviation of the varioiis diseases or disorders =
recited herein. Optionally, or alternately, the instructional material may describe one or more methods of alleviating the diseases or disorders in a cell or a tissue of a mammal. The instructional material of the kit may, for example, be affixed to a container which contains an active compound or be shipped together with a container which contains an active compound. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and an active compound be used cooperatively by the recipient.
[0033] The term, "parenteral" means not through the alimentary canal but by some other route such as subcutaneous, intramuscular, intraspinal, or intravenous.
[0034] The term "phannaceutically acceptable carrier" includes any of the standard pharmaceutical carriers, e.g., a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
[0035] The term "purified" and similar terms relate to the isolation of a molecule or compound in a form that is substantially free (at least 60% free, preferably 75%
free, and most preferably 90% free) from other components normally associated with the molecule or compound in a native environment.
[0036] A "sample" refers preferably to a biological sample from a subject, including, but not liinited to, normal tissue samples, diseased tissue samples, biopsies, blood, saliva, feces, semen, tears, and urine. A sample can also be any other source of material obtained from a subject that contains cells, tissues, or a fluid of interest. A
sample can also be obtained from a cell or tissue culture.
[0037] The terms "standard" or "control" are used ~interchangeably herein and refer to something used for comparison. For example, a'standard can be a known standard agent or compound which is administered or added to a control sample and used for comparing results when measuring said compound in a test sample.
Standard can also refer to an "internal standard," such as an agent or compound which is added at known amounts to a sample and is useful in determining such things as purification or recovery rates when a sample is processed or subjected to purification or extraction procedures before a marker of interest is measured.
[0022] An" analog" of a chemical compound is a compound that, by way of example, resembles another in structure but is not necessarily an isomer (e.g., 5-fluorouracil is an analog of thymine).
[0023] The terms "cell," "cell line," and "cell culture" may be used interchangeably. A "test" cell, tissue, sample, or subject is one being examined or treated. A "control" cell, tissue, sample, or subject is a cell, tissue, sample, or subject of the same type as a test cell, tissue, sample, or subject. The control may, for example, be examined at precisely or nearly the same time the test cell, tissue, sample, or subject is examined. The control may also, for example, be examined at a time distant from the time at which the test cell, tissue, sample, or subject is examined, and the results of the examination of the control may be recorded so that the recorded results may be compared with results obtained by examination of a test cell, tissue, sample, or subject. The control may also be obtained from another source or similar source other than the test group or a test subject, where the test sample is obtained from a subject suspected of having a disease or disorder for which the test is being performed.
[0024] A "pathoindicative" cell, tissue, or sample is one which, when present, is an indication that the animal in which the cell, tissue, or sample is located (or from which the tissue was obtained) is afflicted with a disease or disorder. For example, the presence of one or more breast cells in a lung tissue of an animal is an indication that the.animal is afflicted with metastatic breast cancer.
[0025] A tissue "normally comprises" a cell -if one or more of the cell are present in the tissue in an animal not afflicted with a disease or disorder.
[0026] The word "detect" and its grammatical variants refer to measurement of the species without quantification. The terms "detect" and "identify"- are used interchangeably herein. The words "determine" or "measure" and their grammatical variants refer to measurement of the species with quantification. The terms "determine" or "measure" are used interchangeably herein.
[0027] A "detectable marker" or a` reporter molecule" is an atom or a molecule that permits the specific detection of a compound comprising the marker in the presence of similar compounds without a marker. Examples of detectable markers or reporter molecules include, e.g., radioactive isotopes, antigenic determinants, enzymes, nucleic acids available for hybridization, chromophores, fluorophores, chemiluminescent molecules, electrochemically detectable molecules, and molecules that provide for altered fluorescence-polarization or altered light-scattering.
[0028] A"disease ' is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal's health continues to deteriorate. In contrast, a "disorder" in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal's state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal's state of health.
[0029] The term "effective amount" means an amount sufficient to produce a selected effect. For example, an effective amount of an S 1P receptor antagonist is an amount that decreases the cell signaling activity of the S 1 P receptor.
[0030] A "functional" molecule is a molecule in a form in which it exhibits a property by which it is characterized. For example, a functional enzyme is one which exhibits the catalytic activity by which the enzyme is characterized.
[0031] The term "inhibit" refers to the ability of a compound to reduce or impede a described function. Preferably, inhibition is by at least 10%, more preferably by at least 25%, even more preferably by at least 50%; and most preferably, the function is inhibited by at least 75%.
[0032] The term "instructional material" includes a publication, a recording;
a diagram, or any other medium of expression, which can be used to comrnunicate the usefulness, in the kit for effecting alleviation of the varioiis diseases or disorders =
recited herein. Optionally, or alternately, the instructional material may describe one or more methods of alleviating the diseases or disorders in a cell or a tissue of a mammal. The instructional material of the kit may, for example, be affixed to a container which contains an active compound or be shipped together with a container which contains an active compound. Alternatively, the instructional material may be shipped separately from the container with the intention that the instructional material and an active compound be used cooperatively by the recipient.
[0033] The term, "parenteral" means not through the alimentary canal but by some other route such as subcutaneous, intramuscular, intraspinal, or intravenous.
[0034] The term "phannaceutically acceptable carrier" includes any of the standard pharmaceutical carriers, e.g., a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.
[0035] The term "purified" and similar terms relate to the isolation of a molecule or compound in a form that is substantially free (at least 60% free, preferably 75%
free, and most preferably 90% free) from other components normally associated with the molecule or compound in a native environment.
[0036] A "sample" refers preferably to a biological sample from a subject, including, but not liinited to, normal tissue samples, diseased tissue samples, biopsies, blood, saliva, feces, semen, tears, and urine. A sample can also be any other source of material obtained from a subject that contains cells, tissues, or a fluid of interest. A
sample can also be obtained from a cell or tissue culture.
[0037] The terms "standard" or "control" are used ~interchangeably herein and refer to something used for comparison. For example, a'standard can be a known standard agent or compound which is administered or added to a control sample and used for comparing results when measuring said compound in a test sample.
Standard can also refer to an "internal standard," such as an agent or compound which is added at known amounts to a sample and is useful in determining such things as purification or recovery rates when a sample is processed or subjected to purification or extraction procedures before a marker of interest is measured.
[0038] A"subject" of analysis, diagnosis, or treatment is an animal. Such animals include mammals, preferably a human.
[0039] A "therapeutic" treatment is a treatment administered to a subject who exhibits signs of pathology for the purpose of diminishing or elinminating those signs.
[0040] A "therapeutically effective amount" of a compound is that amount of compound which is sufficient to provide a beneficial effect to the subject to which the compound is adniinistered.
[0041] The term "treating" includes prophylaxis of the specific disorder or condition, or alleviation of the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms.
[0042] As used herein, the term "pharmaceutically acceptable carrier" includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, hydroxypropyl beta-cyclodextrins (HQ-propyl beta cyclodextrins), water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the U.S. Federal government or listed in the U.S. Pharmacopeia for use in animals, including humans.
[0043] As used herein, the term "pharmaceutically-acceptable salt" refers to salts which retain the biological effectiveness and properties of compounds for practicing the disclosed method and which are not biologically or otherwise undesirable.
In many cases, the compounds for practicing the disclosed method are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl .. , groups or groups similar thereto.
[0044] The general chemical terms used in the description of the compounds for practicing the disclosed method have their usual meanings. For example, the term "alkyl" by itself or as part of another substituent means a straight or branched aliphatic chain having the stated number of carbon atoms.
[0045] The term "halo" or "halogen" includes brorno, chloro, lluoro, and iodo:
[0039] A "therapeutic" treatment is a treatment administered to a subject who exhibits signs of pathology for the purpose of diminishing or elinminating those signs.
[0040] A "therapeutically effective amount" of a compound is that amount of compound which is sufficient to provide a beneficial effect to the subject to which the compound is adniinistered.
[0041] The term "treating" includes prophylaxis of the specific disorder or condition, or alleviation of the symptoms associated with a specific disorder or condition and/or preventing or eliminating said symptoms.
[0042] As used herein, the term "pharmaceutically acceptable carrier" includes any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, hydroxypropyl beta-cyclodextrins (HQ-propyl beta cyclodextrins), water, emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The term also encompasses any of the agents approved by a regulatory agency of the U.S. Federal government or listed in the U.S. Pharmacopeia for use in animals, including humans.
[0043] As used herein, the term "pharmaceutically-acceptable salt" refers to salts which retain the biological effectiveness and properties of compounds for practicing the disclosed method and which are not biologically or otherwise undesirable.
In many cases, the compounds for practicing the disclosed method are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl .. , groups or groups similar thereto.
[0044] The general chemical terms used in the description of the compounds for practicing the disclosed method have their usual meanings. For example, the term "alkyl" by itself or as part of another substituent means a straight or branched aliphatic chain having the stated number of carbon atoms.
[0045] The term "halo" or "halogen" includes brorno, chloro, lluoro, and iodo:
[0046] The term "haloalkyl" refers to an alkyl radical bearing at least one halogen substituent, for example, chloromethyl, fluoroethyl or trifluoromethyl and the like.
[0047] The term "alkyl or C1-CIo alkyl" represents a branched or linear alkyl group having from one to six carbon atoms. Typically Cl-CIo alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, and the like. The term "lower alkyl"
refers to branched or straight chain alkyl groups comprising one to about six carbon atoms, including methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, neopentyl and the like.
[0048] The term "alkenyl or C2-Clo alkenyl" represents an olefinically unsaturated branched or linear group having from 2 to 10 carbon atoms and at least one double bond. Examples of such groups include, but are not Iimited to, 1-propenyl, 2-propenyl, 1, 3-butadienyl, 1-butenyl, hexenyl, pentenyl, and the like.
[0049] The term "alkynyl or C2-Clo alkynyl," refers to an unsaturated branched or linear group having from 2 to 10 carbon atoms and at least one triple bond.
Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, and the like.
[0050] The term "C3-C8 cycloalkyl," represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
[0051] The term "optionally substituted" refers to substitution with from zero to four substituents, wherein the substituents are each independently selected.
Each of the independently selected substituents may be the same or different than other substituents.
[0052] As used herein the term "aryl" refers to a mono or bicyclic C5-Clo carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, benzyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. The term "optionally substituted aryl" includes aryl compounds having from zero to four substituents, and a "substituted aryl" includes aryl com.pounds having one to four substituents, wherein the substituents include groups such as, for example, a1kyl, halo or amino substituents.
[0047] The term "alkyl or C1-CIo alkyl" represents a branched or linear alkyl group having from one to six carbon atoms. Typically Cl-CIo alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, t-butyl, pentyl, hexyl, heptyl, octyl, and the like. The term "lower alkyl"
refers to branched or straight chain alkyl groups comprising one to about six carbon atoms, including methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, neopentyl and the like.
[0048] The term "alkenyl or C2-Clo alkenyl" represents an olefinically unsaturated branched or linear group having from 2 to 10 carbon atoms and at least one double bond. Examples of such groups include, but are not Iimited to, 1-propenyl, 2-propenyl, 1, 3-butadienyl, 1-butenyl, hexenyl, pentenyl, and the like.
[0049] The term "alkynyl or C2-Clo alkynyl," refers to an unsaturated branched or linear group having from 2 to 10 carbon atoms and at least one triple bond.
Examples of such groups include, but are not limited to, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, and the like.
[0050] The term "C3-C8 cycloalkyl," represents cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
[0051] The term "optionally substituted" refers to substitution with from zero to four substituents, wherein the substituents are each independently selected.
Each of the independently selected substituents may be the same or different than other substituents.
[0052] As used herein the term "aryl" refers to a mono or bicyclic C5-Clo carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, benzyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like. The term "optionally substituted aryl" includes aryl compounds having from zero to four substituents, and a "substituted aryl" includes aryl com.pounds having one to four substituents, wherein the substituents include groups such as, for example, a1kyl, halo or amino substituents.
[0053] The term "arylalkyl" refers to any aryl group which is attached to the parent moiety via the alkyl group, e.g., aryl(CI -Cs alkyl). Thus, the term (C5-C6 aryl)(C5-C8 alkyl) refers to a five or six membered aromatic ring that is attached to the parent moiety via the C5-C$ alkyl group.
[0054] The term "heterocyclic group" refers to an optionally substituted mono-or bicyclic carbocyclic ring system containing from one to three heteroatoms wherein the heteroatoms are selected from the group consisting of oxygen, sulfur, and nitrogen.
[0055] As used herein the term "heteroaryl" refers to an optionally substituted mono- or bicyclic carbocyclic ring system having one or two aromatic rings containing from one to three heteroatoms wherein the heteroatoms are selected from the group consisting of oxygen, sulfur, and nitrogen. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, pyridyl and the like.
[0056] The term "bicyclic" represents either an unsaturated or saturated stable 7-to 12-membered bridged or fused bicyclic carbon ring. The bicyclic ring may be attached at any carbon atom which affords a stable structure. The term includes, but is not limited to, naphthyl, dicyclohexyl, dicyclohexenyl, and the like.
[00571 The term "ECSQ of an agent" refers to that concentration of an agent at which a given activity, including binding of sphingosine or other ligand of an receptor and/or a functional activity of a SIP receptor (e.g., a signaling activity), is 50% maximal for that S 1P receptor. Stated differently, the ECSO is the concentration of agent that gives 50% activation, when 100% activation is set at the amount of activity of the S1P receptor which does not increase witli'theaddition of more ligand/agonist and 0% is set at the amount of activity in the assay in the'absence of added ligand/agonist.
[0058] The terms "phosphate analog" and "phosphonate analog" comprise analogs of phosphate and phosphonate wherein the phosphorous atom is in the +5 oxidation state and one or more of the oxygen atoms is replaced with a non-oxygen moiety, including for example, the phosphate analogs phosphorothioate, phosphoro-dithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate;
phosphoranilidate, phosphorami date, boronophosphates, and the like, including associated counterions, e.g., hydrogen, NH4, Na, and the like if such counterions are present.
[0059] The compounds for practicing the disclosed method may exist in tautomeric forms and include both mixtures and separate individual tautomers.
For example, the following structure:
N-Z-\NH
\---J is understood to represent a mixture of the structures:
N_Z-1-\NH HNf ~ N
\--j as well as \ __j .[0060] The terms 16:0, 18:0, 18:1, 20:4 or 22:6 hydrocarbon refers to a branched or straight alkyl or alkenyl group, wherein the first integer represents the total number of carbons in the group and the second integer represent the number of double bonds in the group.
[0061] As used herein, an "S 1P modulating agent" refers to a compound or composition that is capable of inducing a detectable change in S 1P receptor activity in vivo or in vitro (e.g., at least 10% increase or decrease in S 1P activity as measured by a given assay such as the bioassay described in the examples and known in the art.
"S 1P receptor," as used herein, refers to all of the S iP receptor subtypes (for example, the S1P receptors S1PI, S1P2, SiP3, S IP4, and S1P5), unless the specific subtype is indicated.
[0062] The S 1 P analogs for practicing the disclosed method can contain one or more asymmetric centers in the.molecule. A structure that does not designate the stereochemistry is to be understood as embracing all the various optical isomers, as well as racemic mixtures thereof.
[0063] The disclosed method includes the use of sphingosine 1-phosphate (S 1P) analogs that have activity as receptor agonists at one or more S 1P receptors, specifically the S 1P,, S 1P4 and S lP5 receptor types. The disclosed method also includes compounds that have a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates particularly where the alpha substitution is a halogen and phosphothionates.
[0064] In one embodiment, the S I P receptor agonists have the general structure of Formula (IIA):
C~
~
(CH2). X
IIA
wherein n is 0, 1, 2 or 3, X is selected from hydroxyl (-OH), phosphate (-OP03H2), phosphonate (-CH2PO3H2), alpha-substituted phosphonate (including: -CHFPO3H2, -CF2PO3H2, -CHOHPO3H2i -C=OPO3H2) , wherein R' is selected from the group consisting of hydrogen, halogens (wherein F or Cl are the preferred halogens), (Ci-C6) alkyl, such as, methyl, ethyl, and propyl, or halo-, hydroxy-, alkoxy-, cyano-substituted (CI-C6) alkyl, such as, tri-fluoromethyl. The R 2 group is selected from the group consisting of alkyl, alkenyl, alkynyl, alkyl substituted aryl, alkyl substituted cycloalkyl, arylalkyl and arylalkyl substituted aryl. In R 2 the chain lengths of 5-8 carbon atoms are preferred, or a pharmaceutically acceptable salt thereof.
[0065] In a specific embodiment, the compounds having formula (II) can have R, selected from the group consisting of H, halo (e.g., F or Cl), methyl, tri-fluoromethyl, ethyl, propyl or other lower alkyl (C i- C6) or halo-, hydroxy-, alkoxy-, cyano-substituted lower alkyl group; and R2 selected fr'orti the group consisting of alkyl, alkenyl, alkynyl, alkyl (optionally substituted aryl), alkyl (optionally substituted cycloalkyl), arylalkyl, and arylalkyl (optionally substituted aryl) with chain lengths of 5-8 carbon atoms preferred.
[00661 The invention provides a method for treating neuropathic pain including administering to a subject in need thereof of a therapeutically acceptable amount-of a compound of formula (I) or forinula (II), or a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (1) or formula (II), and a pharmaceutically-acceptable carrier.
[0067] The disclosed method also includes the use of pharmaceutical compositions including a compound of formula (I) or formula (II), and a pharmaceutically-acceptable carrier. The compounds of formula (I) or formula (II) can be formulated as pharmaceutical compositions using standard pharmaceutically acceptable carriers, fillers, solubilizing agents and stabilizers known to those skilled in the art. For example, a pharmaceutical composition comprising a compound of formula (1) or formula (11), or analog, derivative, or modification thereof, as described herein, is used to administer the compound to a subject.
[0068] A specific value for a lower alkyl group is ethyl or propyl.
[0069] A specific value for halo is fluorine or chlorine.
[0070] A specific value for X is hydroxy or OP03H2.
[0071] A specific value for the alpha-substituted phosphonate group is CHFPO3H2, CF2PO3H2, CHOHPO3H2, -C=OP03H2) or thiophosphate (OPO2SH2).
[0072] A specific value for R' is hydrogen.
[0073] A specific value for R2 is C5-C$alkyl.
[0074] A more specific value for R2 is heptyl, octyl, nonyl,-O-heptyl, -C(=O)heptyl, or CH3-CH2-O-CH2-CH2-O-CH2-CH2-O-.
[0075] A more 'specific value for R2 is octyl, or -O-heptyl.
[0076] A more specific value for R2 is octyl.
[0077] A specific value for n is I or 2.
[0078] Specific cycloalkyl groups having a double bond include:
DH2 ~X X ~X
or [0079] A compound for practicing the disclosed method has an R2 group placed para to the cycloalkyl ring.
[0080] A specific compound for practicing the disclosed,method has the R' group placed ortho or meta to R2.
[0081] A specific compound for practicing the disclosed method has the R2 group placed para to the benzylic cycloalkyl group (e.g., 1,4).
[0082] Non-limiting examples of esters of the disclosed compounds include compounds where the X group is, -Y-P-"
wherein Y is selected from the group consisting of 0, CH2, CHOH, CHF, CFZ, and II
-C-, and R9 and R10 are independently selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aryloxy, O 0 a O ~~ , O v~ a ~ ~ O~O ~O y O
_ > y CH3CHO ' O
O
O
N /Ri O_Ri i .,~NHa and H O O O/\i wherein R" is selected from the group consisting of C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, and optionally substituted aryl. Particularly preferr,ed R9 and R10 groups are alkoxy, OO O--/, Oy 0 O. and O
[0083] A specific compound of formula (II) is VPCOI091, where X is -OH~ R'- is hydrogen, R2 is octane (C$H17), n is 2, and the R2 group is in the para-po"sitiori on the phenyl ring. The formula is:
OH
[0084] VPC0T091 has two chiral centers (the quaternary carbon and benzylic carbon that is part of the cyclopentyl ring) and thus four isomers (diastereomers) are conceivable. VPC01091 is a mixture of these four isomers but the relative amount of each isomer is not known, but available evidence indicates that the four isomers are present in about equal amounts. The individual isomers, A-D, have the formulas:
-OH
i ~iNH2 ''-OH, and i uNF{2 OH
[0085] These compounds can be prepared as a mixture and separated by chromatography. Exemplary ccSnditions for separation are as follows: Column:
Chiralpak AD 4.6 mm ID x 250 mm, Mobile Phase: HexlEtOH/MeOH/DEA =
95/2.5/2.5/0.03, Flow Rate: 1 mL/min, Detector: UV 220 nm, Column Temp: 40 C, or Column Temp: 25 C. The order of isomer elution was D, C, B, and A.- After=
separation; it was found that two isomers, B and D, were not phosphorylated by the SPHK2 enzyme in vitro. However, when phosphorylated prior to testing the phosphorylated compounds were found to be active agonists of the S 1 P
receptors.
[0086] Another specific compound of formula (II) is VPC01211 where X is OP03H2, R' is hydrogen, R2 is octane (CSHi7), n is 2, and the R2 group is in the para-position on the phenyl ring. The formula is:
NHZ
ii O-P-OH
[0087] Another specific compound of formula (II) is VPC02162, where X is OH, R' is hydrogen, R2 is octane (C8H17), n is 2, and the R 2 group is in the rneta-position on the phenyl ring. The formula is:
NHZ
OH
[0088] Another specific compound of formula (II) is VPC02164 where X is OP03H2, R' is hydrogen, R2 is octane (C8H17), n is 2, and the R2 group is in the rneta-position on the phenyl ring. The formula is:
O"~PO
HOA ~OH
[0089] Additional examples of disclosed compounds that include heteroatoms (e.g., N, S, 0) and/or double bonds in the cycloalkyl ring include the structures below:
Nt-`~NH2 NH2 OH, HN OH, NH2 ~NH2 O OH, O OH7 \ N NH
S OH, sN OH
\ \
HN OH, S OH, NH2 \ ( , NH2 NOH
~ , OH, OH, OH, or OH
[0090] A synthetic route to prepare compound for practicing the disclosed method, VPC01091 (6) and VPC01211 (7), is provided.in'the scheme in Fig. 1.
Additional compounds of formula (I) or formula (11) can be prepared by a persan skilled in the art using known modifications to procedures from the schemes and detailed descriptions in the specific examples herein.
[0091] Additional compounds of formula (I) or (11) having,the general formula (111) are illustrated below. The specific variables are recited in Table 1:
R
. ~ /
(CH2)n X
(III) Table 1 Compound R n X
VPC02004 C7Hi5 2 OH
VPC01091 C$H 2 OH
VPC02033 C9H19 2 OPOsH2 VPC01289 C1oHa1 2 OH
VPC01292 QoHa1 2 OP03H2 VPC01220 C$H17 I OH
VPC01222 CxH 1 OPO3H2 [0092] The present invention also provides a method for the use of esters of the compounds of formula (I) or formula (H), e.g., phosphate esters or phosphonate esters as described herein. In addition, the disclosed method include's pharmaceutically acceptable salts of the compounds of formula (I) or formula (II). The disclosed method provides all possible isomers of the structures described by formula (1) or formula (II), noting that when ri-is one (cyclobutane) the compound is symmetric and lacks chiral centers, but cis and trans forms exist.
[0093] Pharmaceutical compositions comprising one or more disclosed compounds can be administered to a subject in need thereof by any number of routes and means including, but not limited to, topical, oral, buccal, intravenous, intramuscular, intra arterial, intramedullary, intrathecal, intraventricular, transdermal, l8 subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, vaginal, ophthalmic, pulmonary, or rectal means. The oral route is typically employed for most conditions requiring the disclosed compounds. Preference is given to intravenous injection or infusion for the acute treatments. For maintenance regimens, the oral or parenteral, e.g. intramuscular or subcutaneous, route is preferred.
[0094] One of ordinary skill in the art would appreciate that the disclosed compounds can be administered at varying doses and at varying times, depending on such conditions as the health, age, weight, and sex of the subject. One of ordinary skill in the art would also appreciate that the disclosed compounds can be administered to a subject via different routes.
[0095] In accordance with one aspect, the method provides administration of a composition that includes a disclosed compound, or an analog, derivative, or modification thereof, and albumin, e.g., the composition comprises at least one disclosed compound, a pharmaceutically acceptable carrier and 0.1-1.0%'o albumin.
Albumin can function as a buffer to improve the solubility of the compounds.
In one aspect, albumin is not added.
[0096] In one aspect, the pharmaceutical compositions useful for practicing the disclosed method may be administered to deliver a dose of between I ng/kg/day and 100 mg/kg/day. In another embodiment, the pharmaceutical compositions useful for practicing the disclosed method may be administered to deliver a dose of between 1 ng/kg/day and 100 g/kg/day.
[0097] Pharmaceutically acceptable carriers which are useful include, but are not limited to, glycerol, water, saline, ethanol, and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).
[0098] The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension br solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non toxic parenterally acceptable diluent or solvent, such as water or 1,3 butane diol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides.
[0099] The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.
[00100] Modification of pharmaceutical compositions for administration to humans in order to prepare the compositions for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation.
Subjects to which administration of the pharmaceutical compositions of the disclosed method is contemplated include, but are not limited to, humans and other primates, and mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.
[00101] A pharmaceutical composition may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a "unit dose" is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The arnount of the active ingredient is -generally equal to the dosage of the active ingredient which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
[00102] The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in the pharmaceutical compositions will vary, depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.
[00103] In addition to the active ingredient, pharmaceutical compositions may further comprise one or more additional pharmaceutically active agents.
Particularly contemplated additional agents include anti-emetics and scavengers such as cyanide and cyanate scavengers.
[00104] Controlled- or sustained-release formulations of a pharmaceutical composition may be made using conventional technology.
[00105] In some cases, the dosage forms to be used can be provided as slow or controlled-release of one or more active ingredients therein using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions.
Controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the pharmaceutical compositions. Thus, single unit dosage forms for oral administration, such as tablets, capsules, gelcaps, and caplets that are adapted for controlled-release are encompassed by the disclosed method.
[00106] Most controlled-i-elease formulations are designed to initially release an amount of drug that promptly produces the desired therapeutic effect, and gradually and continually release other amounts of drug to maintain this level of therapeutic effect over an extended period of time. In order to maintain this constant level_ of drug in the body, the drug must'be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
[00107] Controlled-release of an active ingredient can be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds.
[00108] Powdered and granular formulations of a pharmaceutical preparation may be prepared using known methods. Such formulations may be administered directly to a subject, used, for example, to form tablets, to fill capsules, or to prepare an aqueous or oily suspension or solution by addition of an aqueous or oily vehicle thereto. Each of these formulations may further comprise one or more of dispersing or wetting agent, a suspending agent, and a preservative. Additional excipients, such as fillers and sweetening, flavoring, or coloring agents, may also be included in these formulations.
[00109] As used herein, an "oily" liquid is one which comprises a carbon-containing liquid molecule and which exhibits a less polar character than water.
[00110] A formulation of a pharmaceutical composition for oral administration may be prepared, packaged, or sold in the form of a discrete solid dose unit including, but not limited to, a tablet, a hard or soft capsule, a cachet, a troche, or a lozenge, each containing a predetermined amount of the active ingredient. Other formulations for oral administration include, but are not limited to, a powdered or granular formulation, an aqueous or oily suspension, an aqueous or oily solution, a paste, a gel, a toothpaste, a mouthwash, a coating, an oral rinse, or an emulsion. The terms oral rinse and mouthwash are used interchangeably herein.
[00111] The disclosed method includes a kit comprising a compound or composition useful for preventing or treating pain in a subject and an instructional material which describes administering the compound or a composition comprising the compound to a cell or an animal. This should be construed to include other embodiments of kits that are known to those skilled in the art, such as a kit comprising a (preferably sterile) solvent for dissolving or suspending the disclosed composition prior to administering the compound to a cell or an animal.
Preferably the animal is a human.
[00112] It will be appreciated by those skilled in the art that the disclosed compounds having a chiral center may exist in and be isolated iri optically ac'tive'and*
racemic forms. Some compounds may exhibit polymorphism. It is to be understood that any racemic, optically-active, polymorphic, or stercoisomeric form, or mixtures thereof, of a disclosed compound, which possess the useful properties described herein is included.' It is known in the art how to prepare optically active forms (for example, resolution of the racemic form by recrystallization techniques, synthesis from optically-active starting materials, by chiral synthesis, or chromatographic separation using a chiral stationary phase) and how to determine S1P agonist activity using the standard tests described herein, or using other similar tests which are well known in the art.
[00113] In cases where compounds are sufficiently basic or acidic to form acid or base salts, use of the compounds as salts may be appropriate. Examples of acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate.
Inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
[00114] Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids.. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
[00115] Pharmaceutically-acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl 'amines; trialkyl amiites, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines,"
di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di-and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three sub.stituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group. Non-limiting examples of amines include isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, trometharnine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like. It should also be understood that other carboxylic acid derivatives would be useful in to practice the disclosed method, for example, carboxylic acid amides, including carboxamides, lower alkyl carboxamides, dialkyl carboxamides, and the like.
[00116] Salts may be obtained using standard procedures well known in the art.
For example reaction of a sufficiently basic compound such as an amine with an acid can afford a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of organic (e.g., carboxylic) acids can also be made.
Examples [00117] The invention is now described with reference to the following examples.
These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these'examples, but rather should be construed to encompass any and all variations: which become evident as a result of the teachings provided herein.
Example 1: (l-amino-3-(4-octylphenyl)cyclopentyl)methanol (6) [00118] A.: 3-(4-iodophenyl)cyclopentanone (1) 0.23g palladium(II) acetate (0.1 eq) and 0.23g antimony(III) chloride (0.1 eq) were added to 80 mL acetic acid solution of 2-cyclopenten-l-one 0.82g (10 mmol), 4-iodophenylboropic acid 2.48g *
(10 mmol) and sodium acetate 1.6g (20 mmol) under N2 atmosphere. After being stirred for 24 hours at 25 C, the black precipitation was filte'red off and the filtrate was diluted with 250 mL of brine, and then extracted twice with 50 mL
methylene chloride. The organic extract was stirred with saturated NaHCO3 solution for minutes, then washed with brine and dried over MgSO4. Removal of solvent resulted in a yellow oil, further purification by flash column (chloroform) gave 1.92g (67%) product as a white solid. J. Org. Chem., 1995, 60, 883-888. 'H NMR (CDC13) S
7.63 (d, 2H, ArH), 7.00 (d, 2H, ArH), 3.35 (m, 1H, ArCHCC), 2.7-1.8 (m, 6H, cyclo-pentyl); 13C NMR (CDC13) fi 218, 143, 138, 129, 95, 46, 42, 39, 31.
[00119] B.: 3-(4-(oct-l-ynyl)phenyl)cyclopentanone (2) 1.1 g (10 mmol) of 1-octyne was added to a flame dried 25 mL flask charged with 10 mL THF solution of 1.43g (5 mmol) of 1. After degassing for 30 minutes, 2 mL triethylamine, 5 mg of CuI and 10 mg of Pd(PPh3)4 were added under N2 protection. The reaction was complete in 6 hrs, after removal of solvent and volatile reagent, the mixture was column chromatographed with chloroform to provide 1.34g (99%) yellow oil. 1H
NMR (CDCl3) 8 7.35 (d, 2H, ArH), 7.15 (d, 2H, ArH), 3.37 (m, 1 H, ArCHCC), 2.7-2.2 (m, 6H, cyclo-pentyl), 1.95 (m, 2H, CCCH CHZ), 1.6-1.2 (m, 8H, CH2), 0.89 (t, J=6Hz, 2H, CH3); 13C NMR (CDCl3) S 220, 143, 132, 127, 122, 91, 80, 46, 42, 39, 32, 31, 29, 29, 23, 20, 14.
[00120] C.: 3-(4-octylphenyl)cyclopentanone (3). Several drops of formic acid and catalytic amount 5% Pd/C was added to a 25 mL flask charged with 10 mL
methanol and 1.34g (5 mmol) of 2. The reaction vessel was flushed with H2, 3 times, and then mounted with a H2 balloon. After two days of hydrogenolysis, the solute was filtered through a pad of silica, and concentrated to provide a yellow oil. 1.32g (98%) product was collected. 'H NMR (CDC13) fi 7.18 (s, 4H, ArH), 3.38 (m, IH, ArCHCC), 2.60 (t, 2H, CCCH CHZ), 2.45-1.91 (m, 6H, cyclo-pentyl), 1.64-1.15 (m, 12H, CHz), 0.90 (t, 3H, CH3); 13C NMR (CDC13) 8 220, 142, 140, 129, 127, 46, 42, 39, 36, 32, 32, 32, 30, 30, 29, 23, 14.
[00121] D.: 1-amino-3-(4-octylphenyl)cyclopentanecarbonitrile (4) 3.20g (1.1.8 mmol) of 3, sodium cyanide 1.15g (23.5 mmol) and ammonium chloride 1.25g (23.5.
mmol) were added to 20 mL of ammonium hydroxide. The mixture was extracted twice with 10 mL of methylene chloride after vigorously stirring overnight.
The organic extraction was dried and concentrated to provide a yellow oil 3.30g.
The crude product is used for next step without further purification. J. Med.
Chem., 1986, 29, 1988-1995.
[00122] E.: 1-amino-3-(4-octylphenyl)cyclopentanecarboxylic acid (5). 3.3g (11.2 mmol) of 4 and 50 mL concentrated hydrochloric acid was heated to 70 C
and stirred overnight. The resulting clear aqueous solution was evaporated to dryness. 10 mL water was added and dried again. This process was repeated several times.
The crude product was washed with water and acetone to provide a white fine powder.
Yield was 1.7g (45%). 'H NMR (d6-DMSO) 8 7.25-7.06 (m, 4H, ArH), 3.21 (m, 1H, ArCHCC), 2.38-1.62 (m, 6H, cyclo-pentyl), 1.49-1.20 (m, 14H, CHZ), 0.81 (t, J=6Hz, 3H, CH3); '3 C NMR (d6-DMSO) S 175, 141, 140, 64, 51, 46, 45, 44, 36, 35, 35, 34, 32, 32, 29, 29, 23, 15.
[00123] F.: (1-amino-3-(4-octylphenyl)cyclopentyl)methanol (6). 63.4 mg (0.2 mmol) of 5 and 27 mg (0.6 mmol) sodium borohydride were dissolved in 3 mL of THF. After the solution was cooled to 0 C, 51 mg (0.2 mmol) 12 was dissolved in 1 mL THF and added dropwise. Then the vessel was fitted with a condenser and the reaction mixture was refluxed under N2 for 5 hrs. Excess NaBH4 was quenched with methanol. After removal of solvent, 2 mL water and 5 mL methylene chloride was added, the mixture was stirred for about 1 hr until the organic layer became clear.
The organic phase was collected and aqueous phase was further extracted twice with methylene chloride. The combined organic extraction was dried and concentrated to provide 43 mg (71 Io) of the crude product. Further purification on TLC with methanol/chloroform (5:95) provided 13 mg of clear oil. J. Org. Chem., 1993, 58, 3568-3571. 'H NMR (CD3OD) S 7.11 (m, 4H, ArH), 3.80 (t, J=7.5Hz, 1 H, c-pentyl-CH2O), 3.67 (t, J=7.5Hz, 1 H, c-pentyl-CH2O), 3.01 (m, 1 H, ArCHCC), 2.55 (t, T 7.5Hz, 2H, ArCH2), 2.29-1.69 (m, 6H, cyclo-pentyl); 1.57 (m; 2H, ArCHZCH ), 1.38-1.28 (m, IOH, CH2), 0.89 (t, J=7.5Hz, 3H, CH3); 13C NMR (CD3COCD3),S
141,.
128, 127, 96, 45, 44, 43, 35, 35; 33, 33, 32, 32, 29, 29, 19, 23, 13. ' Example 2: (1-amino-3-(4-octylphenyl)cyclopentyl)methyl dihydrogen phosphate (7) [00124] 1 mL of 85%*H3P04 was slowly added (by drops) into 0.5g of P205, the acid-anhydride mixture was then heated at 100 C for 1 hour under nitrogen protection. Another 0.5g of P205 and 30 mg of alcohol 6 were added to the poly phosphoric acid and.heated for 5 hours at 100 C. After cooling down to room temperature, 10 mL cold water (0 C) was added to reaction mixture. The product precipitated out as white solid, was collected and washed with water. 31 mg (82%) of green colored product was collected after vacuum drying. MS only two peaks:
M+1=384.4 with 304.4 (hydrolyzed back to 6).
Examnle 3: Separation of Isomers of VPC01091 [00125] The mixture of isomers of compound VPC01091 is preformed using a Chiralpak AD-H 4.6 mm ID x 250 mm column, at 45 C, solvent flow rate: 0.8 mL/min (isocratic), solvent: 95% heptane : 2.5% ethanol : 2.5% methanol (0.2%
diethylamine added as modifier to 95:2.5:2.5 mixture). The run time was 40 min, UVI, wavelength monitored: 254nm. The order of isomer elution was D, C, B, and A.
Example 4: Pain Assay [00126] Test compound, VPC01091 (Drug T, mixture of all isomers), was dissolved in 2% hydroxypropyl beta-cyclodextrin in water and administered to the test group of laboratory rats. The vehicle (Drug V: 2% hydroxypropyl beta-cyclodextrin in water) was administered to the control group of laboratory rats. Each group included 11 animals.
[00127] The identities of 'Drug T' an'd `Drug V' were maintained iry secret to, prevent bias. The test solutions (test compound or vehicle) were intraperitoneally (IP) administered once (day 0), the dose was 10 mg/kg body weight. On day Q, each of the 22 animals was anesthetized, the sciatic nerve bundle on the right side exposed surgically, and crushed mechanically. This is known as the `trauma' model of neuropathic pain. The animals were tested each day for the time required to lift either paw after illumination with small heat lamp. Normal PWL (paw withdrawal latency) time in an adult rat is 10-11 seconds, an untreated rat with a crushed sciatic nerve exhibits thermal hyperalgesia having a PWL time decreases to about 6 seconds.
[00128] Treatment of the animals with VPC01091 (Drug T) prevented the development of thermal hyperalgesia in the affected (crushed nerve) paw, and exhibited an analgesic effect, due to PWL time increases after injury, only on the affected side. The results are illustrated in Figs. 2 and 3.
[00129] Other, non-S1P receptor active, compounds that prevent thermal (or mechanical) allodynia from developing in such models are known. Likewise, drugs that cause general analgesia (e.g., morphine) are known.
Example 5: Analgesic Effects of VPC01091-D
[00130] The compound VPC01091-D was demonstrated to be effective at blocking mechanical allodynia associated with nerve injury in two preclinical models of neuropathic pain, sciatic nerve injury (CCI) and spinal nerve injury (SNL) models using groups of rats (7). In these models, oral treatment with VPC01091-D was started 2 weeks following nerve injury, once the pain was established. A
control group received only vehicle. Following once a day dosing for 5 days, VPC01091-D
(3mg/kg, p.o.) reversed mechanical allodynia by 42 8% in the CCI model. (See Figure 5).
[00131] VPC01091-D (3 mg/kg, p.o.) produced similar analgesic activity (50 10%) in the SNL model. Oral duloxetine, a drug approved for the treatment of neuropathic pain, produces a similar degree of analgesic efficacy in both models at a dose of 30 mg/kg, p.o.
[00132] All references cited herein are expressly incbrporated herein by reference in their entirety into this disclosure. Illustrative embodiments of this disclosure are discussed and refeirence has been made to possible variations within the scope of this disclosi.ure. These and other variations and modifications in the disclosure will be apparent to those skilled in the art without departing from the scope of the disclosure, and it should be understood that this disclosure and the claims shown below are not limited to the illustrative embodiments set forth herein.
[0054] The term "heterocyclic group" refers to an optionally substituted mono-or bicyclic carbocyclic ring system containing from one to three heteroatoms wherein the heteroatoms are selected from the group consisting of oxygen, sulfur, and nitrogen.
[0055] As used herein the term "heteroaryl" refers to an optionally substituted mono- or bicyclic carbocyclic ring system having one or two aromatic rings containing from one to three heteroatoms wherein the heteroatoms are selected from the group consisting of oxygen, sulfur, and nitrogen. Examples of heteroaryl rings include, but are not limited to, furyl, thienyl, pyridyl and the like.
[0056] The term "bicyclic" represents either an unsaturated or saturated stable 7-to 12-membered bridged or fused bicyclic carbon ring. The bicyclic ring may be attached at any carbon atom which affords a stable structure. The term includes, but is not limited to, naphthyl, dicyclohexyl, dicyclohexenyl, and the like.
[00571 The term "ECSQ of an agent" refers to that concentration of an agent at which a given activity, including binding of sphingosine or other ligand of an receptor and/or a functional activity of a SIP receptor (e.g., a signaling activity), is 50% maximal for that S 1P receptor. Stated differently, the ECSO is the concentration of agent that gives 50% activation, when 100% activation is set at the amount of activity of the S1P receptor which does not increase witli'theaddition of more ligand/agonist and 0% is set at the amount of activity in the assay in the'absence of added ligand/agonist.
[0058] The terms "phosphate analog" and "phosphonate analog" comprise analogs of phosphate and phosphonate wherein the phosphorous atom is in the +5 oxidation state and one or more of the oxygen atoms is replaced with a non-oxygen moiety, including for example, the phosphate analogs phosphorothioate, phosphoro-dithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate;
phosphoranilidate, phosphorami date, boronophosphates, and the like, including associated counterions, e.g., hydrogen, NH4, Na, and the like if such counterions are present.
[0059] The compounds for practicing the disclosed method may exist in tautomeric forms and include both mixtures and separate individual tautomers.
For example, the following structure:
N-Z-\NH
\---J is understood to represent a mixture of the structures:
N_Z-1-\NH HNf ~ N
\--j as well as \ __j .[0060] The terms 16:0, 18:0, 18:1, 20:4 or 22:6 hydrocarbon refers to a branched or straight alkyl or alkenyl group, wherein the first integer represents the total number of carbons in the group and the second integer represent the number of double bonds in the group.
[0061] As used herein, an "S 1P modulating agent" refers to a compound or composition that is capable of inducing a detectable change in S 1P receptor activity in vivo or in vitro (e.g., at least 10% increase or decrease in S 1P activity as measured by a given assay such as the bioassay described in the examples and known in the art.
"S 1P receptor," as used herein, refers to all of the S iP receptor subtypes (for example, the S1P receptors S1PI, S1P2, SiP3, S IP4, and S1P5), unless the specific subtype is indicated.
[0062] The S 1 P analogs for practicing the disclosed method can contain one or more asymmetric centers in the.molecule. A structure that does not designate the stereochemistry is to be understood as embracing all the various optical isomers, as well as racemic mixtures thereof.
[0063] The disclosed method includes the use of sphingosine 1-phosphate (S 1P) analogs that have activity as receptor agonists at one or more S 1P receptors, specifically the S 1P,, S 1P4 and S lP5 receptor types. The disclosed method also includes compounds that have a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates particularly where the alpha substitution is a halogen and phosphothionates.
[0064] In one embodiment, the S I P receptor agonists have the general structure of Formula (IIA):
C~
~
(CH2). X
IIA
wherein n is 0, 1, 2 or 3, X is selected from hydroxyl (-OH), phosphate (-OP03H2), phosphonate (-CH2PO3H2), alpha-substituted phosphonate (including: -CHFPO3H2, -CF2PO3H2, -CHOHPO3H2i -C=OPO3H2) , wherein R' is selected from the group consisting of hydrogen, halogens (wherein F or Cl are the preferred halogens), (Ci-C6) alkyl, such as, methyl, ethyl, and propyl, or halo-, hydroxy-, alkoxy-, cyano-substituted (CI-C6) alkyl, such as, tri-fluoromethyl. The R 2 group is selected from the group consisting of alkyl, alkenyl, alkynyl, alkyl substituted aryl, alkyl substituted cycloalkyl, arylalkyl and arylalkyl substituted aryl. In R 2 the chain lengths of 5-8 carbon atoms are preferred, or a pharmaceutically acceptable salt thereof.
[0065] In a specific embodiment, the compounds having formula (II) can have R, selected from the group consisting of H, halo (e.g., F or Cl), methyl, tri-fluoromethyl, ethyl, propyl or other lower alkyl (C i- C6) or halo-, hydroxy-, alkoxy-, cyano-substituted lower alkyl group; and R2 selected fr'orti the group consisting of alkyl, alkenyl, alkynyl, alkyl (optionally substituted aryl), alkyl (optionally substituted cycloalkyl), arylalkyl, and arylalkyl (optionally substituted aryl) with chain lengths of 5-8 carbon atoms preferred.
[00661 The invention provides a method for treating neuropathic pain including administering to a subject in need thereof of a therapeutically acceptable amount-of a compound of formula (I) or forinula (II), or a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (1) or formula (II), and a pharmaceutically-acceptable carrier.
[0067] The disclosed method also includes the use of pharmaceutical compositions including a compound of formula (I) or formula (II), and a pharmaceutically-acceptable carrier. The compounds of formula (I) or formula (II) can be formulated as pharmaceutical compositions using standard pharmaceutically acceptable carriers, fillers, solubilizing agents and stabilizers known to those skilled in the art. For example, a pharmaceutical composition comprising a compound of formula (1) or formula (11), or analog, derivative, or modification thereof, as described herein, is used to administer the compound to a subject.
[0068] A specific value for a lower alkyl group is ethyl or propyl.
[0069] A specific value for halo is fluorine or chlorine.
[0070] A specific value for X is hydroxy or OP03H2.
[0071] A specific value for the alpha-substituted phosphonate group is CHFPO3H2, CF2PO3H2, CHOHPO3H2, -C=OP03H2) or thiophosphate (OPO2SH2).
[0072] A specific value for R' is hydrogen.
[0073] A specific value for R2 is C5-C$alkyl.
[0074] A more specific value for R2 is heptyl, octyl, nonyl,-O-heptyl, -C(=O)heptyl, or CH3-CH2-O-CH2-CH2-O-CH2-CH2-O-.
[0075] A more 'specific value for R2 is octyl, or -O-heptyl.
[0076] A more specific value for R2 is octyl.
[0077] A specific value for n is I or 2.
[0078] Specific cycloalkyl groups having a double bond include:
DH2 ~X X ~X
or [0079] A compound for practicing the disclosed method has an R2 group placed para to the cycloalkyl ring.
[0080] A specific compound for practicing the disclosed,method has the R' group placed ortho or meta to R2.
[0081] A specific compound for practicing the disclosed method has the R2 group placed para to the benzylic cycloalkyl group (e.g., 1,4).
[0082] Non-limiting examples of esters of the disclosed compounds include compounds where the X group is, -Y-P-"
wherein Y is selected from the group consisting of 0, CH2, CHOH, CHF, CFZ, and II
-C-, and R9 and R10 are independently selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aryloxy, O 0 a O ~~ , O v~ a ~ ~ O~O ~O y O
_ > y CH3CHO ' O
O
O
N /Ri O_Ri i .,~NHa and H O O O/\i wherein R" is selected from the group consisting of C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, and optionally substituted aryl. Particularly preferr,ed R9 and R10 groups are alkoxy, OO O--/, Oy 0 O. and O
[0083] A specific compound of formula (II) is VPCOI091, where X is -OH~ R'- is hydrogen, R2 is octane (C$H17), n is 2, and the R2 group is in the para-po"sitiori on the phenyl ring. The formula is:
OH
[0084] VPC0T091 has two chiral centers (the quaternary carbon and benzylic carbon that is part of the cyclopentyl ring) and thus four isomers (diastereomers) are conceivable. VPC01091 is a mixture of these four isomers but the relative amount of each isomer is not known, but available evidence indicates that the four isomers are present in about equal amounts. The individual isomers, A-D, have the formulas:
-OH
i ~iNH2 ''-OH, and i uNF{2 OH
[0085] These compounds can be prepared as a mixture and separated by chromatography. Exemplary ccSnditions for separation are as follows: Column:
Chiralpak AD 4.6 mm ID x 250 mm, Mobile Phase: HexlEtOH/MeOH/DEA =
95/2.5/2.5/0.03, Flow Rate: 1 mL/min, Detector: UV 220 nm, Column Temp: 40 C, or Column Temp: 25 C. The order of isomer elution was D, C, B, and A.- After=
separation; it was found that two isomers, B and D, were not phosphorylated by the SPHK2 enzyme in vitro. However, when phosphorylated prior to testing the phosphorylated compounds were found to be active agonists of the S 1 P
receptors.
[0086] Another specific compound of formula (II) is VPC01211 where X is OP03H2, R' is hydrogen, R2 is octane (CSHi7), n is 2, and the R2 group is in the para-position on the phenyl ring. The formula is:
NHZ
ii O-P-OH
[0087] Another specific compound of formula (II) is VPC02162, where X is OH, R' is hydrogen, R2 is octane (C8H17), n is 2, and the R 2 group is in the rneta-position on the phenyl ring. The formula is:
NHZ
OH
[0088] Another specific compound of formula (II) is VPC02164 where X is OP03H2, R' is hydrogen, R2 is octane (C8H17), n is 2, and the R2 group is in the rneta-position on the phenyl ring. The formula is:
O"~PO
HOA ~OH
[0089] Additional examples of disclosed compounds that include heteroatoms (e.g., N, S, 0) and/or double bonds in the cycloalkyl ring include the structures below:
Nt-`~NH2 NH2 OH, HN OH, NH2 ~NH2 O OH, O OH7 \ N NH
S OH, sN OH
\ \
HN OH, S OH, NH2 \ ( , NH2 NOH
~ , OH, OH, OH, or OH
[0090] A synthetic route to prepare compound for practicing the disclosed method, VPC01091 (6) and VPC01211 (7), is provided.in'the scheme in Fig. 1.
Additional compounds of formula (I) or formula (11) can be prepared by a persan skilled in the art using known modifications to procedures from the schemes and detailed descriptions in the specific examples herein.
[0091] Additional compounds of formula (I) or (11) having,the general formula (111) are illustrated below. The specific variables are recited in Table 1:
R
. ~ /
(CH2)n X
(III) Table 1 Compound R n X
VPC02004 C7Hi5 2 OH
VPC01091 C$H 2 OH
VPC02033 C9H19 2 OPOsH2 VPC01289 C1oHa1 2 OH
VPC01292 QoHa1 2 OP03H2 VPC01220 C$H17 I OH
VPC01222 CxH 1 OPO3H2 [0092] The present invention also provides a method for the use of esters of the compounds of formula (I) or formula (H), e.g., phosphate esters or phosphonate esters as described herein. In addition, the disclosed method include's pharmaceutically acceptable salts of the compounds of formula (I) or formula (II). The disclosed method provides all possible isomers of the structures described by formula (1) or formula (II), noting that when ri-is one (cyclobutane) the compound is symmetric and lacks chiral centers, but cis and trans forms exist.
[0093] Pharmaceutical compositions comprising one or more disclosed compounds can be administered to a subject in need thereof by any number of routes and means including, but not limited to, topical, oral, buccal, intravenous, intramuscular, intra arterial, intramedullary, intrathecal, intraventricular, transdermal, l8 subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, vaginal, ophthalmic, pulmonary, or rectal means. The oral route is typically employed for most conditions requiring the disclosed compounds. Preference is given to intravenous injection or infusion for the acute treatments. For maintenance regimens, the oral or parenteral, e.g. intramuscular or subcutaneous, route is preferred.
[0094] One of ordinary skill in the art would appreciate that the disclosed compounds can be administered at varying doses and at varying times, depending on such conditions as the health, age, weight, and sex of the subject. One of ordinary skill in the art would also appreciate that the disclosed compounds can be administered to a subject via different routes.
[0095] In accordance with one aspect, the method provides administration of a composition that includes a disclosed compound, or an analog, derivative, or modification thereof, and albumin, e.g., the composition comprises at least one disclosed compound, a pharmaceutically acceptable carrier and 0.1-1.0%'o albumin.
Albumin can function as a buffer to improve the solubility of the compounds.
In one aspect, albumin is not added.
[0096] In one aspect, the pharmaceutical compositions useful for practicing the disclosed method may be administered to deliver a dose of between I ng/kg/day and 100 mg/kg/day. In another embodiment, the pharmaceutical compositions useful for practicing the disclosed method may be administered to deliver a dose of between 1 ng/kg/day and 100 g/kg/day.
[0097] Pharmaceutically acceptable carriers which are useful include, but are not limited to, glycerol, water, saline, ethanol, and other pharmaceutically acceptable salt solutions such as phosphates and salts of organic acids. Examples of these and other pharmaceutically acceptable carriers are described in Remington's Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).
[0098] The pharmaceutical compositions may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension br solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the dispersing agents, wetting agents, or suspending agents described herein. Such sterile injectable formulations may be prepared using a non toxic parenterally acceptable diluent or solvent, such as water or 1,3 butane diol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-glycerides.
[0099] The formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with a carrier or one or more other accessory ingredients, and then, if necessary or desirable, shaping or packaging the product into a desired single- or multi-dose unit.
[00100] Modification of pharmaceutical compositions for administration to humans in order to prepare the compositions for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and perform such modification with merely ordinary, if any, experimentation.
Subjects to which administration of the pharmaceutical compositions of the disclosed method is contemplated include, but are not limited to, humans and other primates, and mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, and dogs.
[00101] A pharmaceutical composition may be prepared, packaged, or sold in bulk, as a single unit dose, or as a plurality of single unit doses. As used herein, a "unit dose" is a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The arnount of the active ingredient is -generally equal to the dosage of the active ingredient which would be administered to a subject or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.
[00102] The relative amounts of the active ingredient, the pharmaceutically acceptable carrier, and any additional ingredients in the pharmaceutical compositions will vary, depending upon the identity, size, and condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, the composition may comprise between 0.1% and 100% (w/w) active ingredient.
[00103] In addition to the active ingredient, pharmaceutical compositions may further comprise one or more additional pharmaceutically active agents.
Particularly contemplated additional agents include anti-emetics and scavengers such as cyanide and cyanate scavengers.
[00104] Controlled- or sustained-release formulations of a pharmaceutical composition may be made using conventional technology.
[00105] In some cases, the dosage forms to be used can be provided as slow or controlled-release of one or more active ingredients therein using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions.
Controlled-release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the pharmaceutical compositions. Thus, single unit dosage forms for oral administration, such as tablets, capsules, gelcaps, and caplets that are adapted for controlled-release are encompassed by the disclosed method.
[00106] Most controlled-i-elease formulations are designed to initially release an amount of drug that promptly produces the desired therapeutic effect, and gradually and continually release other amounts of drug to maintain this level of therapeutic effect over an extended period of time. In order to maintain this constant level_ of drug in the body, the drug must'be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
[00107] Controlled-release of an active ingredient can be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds.
[00108] Powdered and granular formulations of a pharmaceutical preparation may be prepared using known methods. Such formulations may be administered directly to a subject, used, for example, to form tablets, to fill capsules, or to prepare an aqueous or oily suspension or solution by addition of an aqueous or oily vehicle thereto. Each of these formulations may further comprise one or more of dispersing or wetting agent, a suspending agent, and a preservative. Additional excipients, such as fillers and sweetening, flavoring, or coloring agents, may also be included in these formulations.
[00109] As used herein, an "oily" liquid is one which comprises a carbon-containing liquid molecule and which exhibits a less polar character than water.
[00110] A formulation of a pharmaceutical composition for oral administration may be prepared, packaged, or sold in the form of a discrete solid dose unit including, but not limited to, a tablet, a hard or soft capsule, a cachet, a troche, or a lozenge, each containing a predetermined amount of the active ingredient. Other formulations for oral administration include, but are not limited to, a powdered or granular formulation, an aqueous or oily suspension, an aqueous or oily solution, a paste, a gel, a toothpaste, a mouthwash, a coating, an oral rinse, or an emulsion. The terms oral rinse and mouthwash are used interchangeably herein.
[00111] The disclosed method includes a kit comprising a compound or composition useful for preventing or treating pain in a subject and an instructional material which describes administering the compound or a composition comprising the compound to a cell or an animal. This should be construed to include other embodiments of kits that are known to those skilled in the art, such as a kit comprising a (preferably sterile) solvent for dissolving or suspending the disclosed composition prior to administering the compound to a cell or an animal.
Preferably the animal is a human.
[00112] It will be appreciated by those skilled in the art that the disclosed compounds having a chiral center may exist in and be isolated iri optically ac'tive'and*
racemic forms. Some compounds may exhibit polymorphism. It is to be understood that any racemic, optically-active, polymorphic, or stercoisomeric form, or mixtures thereof, of a disclosed compound, which possess the useful properties described herein is included.' It is known in the art how to prepare optically active forms (for example, resolution of the racemic form by recrystallization techniques, synthesis from optically-active starting materials, by chiral synthesis, or chromatographic separation using a chiral stationary phase) and how to determine S1P agonist activity using the standard tests described herein, or using other similar tests which are well known in the art.
[00113] In cases where compounds are sufficiently basic or acidic to form acid or base salts, use of the compounds as salts may be appropriate. Examples of acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, a-ketoglutarate, and a-glycerophosphate.
Inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts.
[00114] Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids.. Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
[00115] Pharmaceutically-acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl 'amines; trialkyl amiites, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines,"
di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di-and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three sub.stituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group. Non-limiting examples of amines include isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, trometharnine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like. It should also be understood that other carboxylic acid derivatives would be useful in to practice the disclosed method, for example, carboxylic acid amides, including carboxamides, lower alkyl carboxamides, dialkyl carboxamides, and the like.
[00116] Salts may be obtained using standard procedures well known in the art.
For example reaction of a sufficiently basic compound such as an amine with an acid can afford a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of organic (e.g., carboxylic) acids can also be made.
Examples [00117] The invention is now described with reference to the following examples.
These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these'examples, but rather should be construed to encompass any and all variations: which become evident as a result of the teachings provided herein.
Example 1: (l-amino-3-(4-octylphenyl)cyclopentyl)methanol (6) [00118] A.: 3-(4-iodophenyl)cyclopentanone (1) 0.23g palladium(II) acetate (0.1 eq) and 0.23g antimony(III) chloride (0.1 eq) were added to 80 mL acetic acid solution of 2-cyclopenten-l-one 0.82g (10 mmol), 4-iodophenylboropic acid 2.48g *
(10 mmol) and sodium acetate 1.6g (20 mmol) under N2 atmosphere. After being stirred for 24 hours at 25 C, the black precipitation was filte'red off and the filtrate was diluted with 250 mL of brine, and then extracted twice with 50 mL
methylene chloride. The organic extract was stirred with saturated NaHCO3 solution for minutes, then washed with brine and dried over MgSO4. Removal of solvent resulted in a yellow oil, further purification by flash column (chloroform) gave 1.92g (67%) product as a white solid. J. Org. Chem., 1995, 60, 883-888. 'H NMR (CDC13) S
7.63 (d, 2H, ArH), 7.00 (d, 2H, ArH), 3.35 (m, 1H, ArCHCC), 2.7-1.8 (m, 6H, cyclo-pentyl); 13C NMR (CDC13) fi 218, 143, 138, 129, 95, 46, 42, 39, 31.
[00119] B.: 3-(4-(oct-l-ynyl)phenyl)cyclopentanone (2) 1.1 g (10 mmol) of 1-octyne was added to a flame dried 25 mL flask charged with 10 mL THF solution of 1.43g (5 mmol) of 1. After degassing for 30 minutes, 2 mL triethylamine, 5 mg of CuI and 10 mg of Pd(PPh3)4 were added under N2 protection. The reaction was complete in 6 hrs, after removal of solvent and volatile reagent, the mixture was column chromatographed with chloroform to provide 1.34g (99%) yellow oil. 1H
NMR (CDCl3) 8 7.35 (d, 2H, ArH), 7.15 (d, 2H, ArH), 3.37 (m, 1 H, ArCHCC), 2.7-2.2 (m, 6H, cyclo-pentyl), 1.95 (m, 2H, CCCH CHZ), 1.6-1.2 (m, 8H, CH2), 0.89 (t, J=6Hz, 2H, CH3); 13C NMR (CDCl3) S 220, 143, 132, 127, 122, 91, 80, 46, 42, 39, 32, 31, 29, 29, 23, 20, 14.
[00120] C.: 3-(4-octylphenyl)cyclopentanone (3). Several drops of formic acid and catalytic amount 5% Pd/C was added to a 25 mL flask charged with 10 mL
methanol and 1.34g (5 mmol) of 2. The reaction vessel was flushed with H2, 3 times, and then mounted with a H2 balloon. After two days of hydrogenolysis, the solute was filtered through a pad of silica, and concentrated to provide a yellow oil. 1.32g (98%) product was collected. 'H NMR (CDC13) fi 7.18 (s, 4H, ArH), 3.38 (m, IH, ArCHCC), 2.60 (t, 2H, CCCH CHZ), 2.45-1.91 (m, 6H, cyclo-pentyl), 1.64-1.15 (m, 12H, CHz), 0.90 (t, 3H, CH3); 13C NMR (CDC13) 8 220, 142, 140, 129, 127, 46, 42, 39, 36, 32, 32, 32, 30, 30, 29, 23, 14.
[00121] D.: 1-amino-3-(4-octylphenyl)cyclopentanecarbonitrile (4) 3.20g (1.1.8 mmol) of 3, sodium cyanide 1.15g (23.5 mmol) and ammonium chloride 1.25g (23.5.
mmol) were added to 20 mL of ammonium hydroxide. The mixture was extracted twice with 10 mL of methylene chloride after vigorously stirring overnight.
The organic extraction was dried and concentrated to provide a yellow oil 3.30g.
The crude product is used for next step without further purification. J. Med.
Chem., 1986, 29, 1988-1995.
[00122] E.: 1-amino-3-(4-octylphenyl)cyclopentanecarboxylic acid (5). 3.3g (11.2 mmol) of 4 and 50 mL concentrated hydrochloric acid was heated to 70 C
and stirred overnight. The resulting clear aqueous solution was evaporated to dryness. 10 mL water was added and dried again. This process was repeated several times.
The crude product was washed with water and acetone to provide a white fine powder.
Yield was 1.7g (45%). 'H NMR (d6-DMSO) 8 7.25-7.06 (m, 4H, ArH), 3.21 (m, 1H, ArCHCC), 2.38-1.62 (m, 6H, cyclo-pentyl), 1.49-1.20 (m, 14H, CHZ), 0.81 (t, J=6Hz, 3H, CH3); '3 C NMR (d6-DMSO) S 175, 141, 140, 64, 51, 46, 45, 44, 36, 35, 35, 34, 32, 32, 29, 29, 23, 15.
[00123] F.: (1-amino-3-(4-octylphenyl)cyclopentyl)methanol (6). 63.4 mg (0.2 mmol) of 5 and 27 mg (0.6 mmol) sodium borohydride were dissolved in 3 mL of THF. After the solution was cooled to 0 C, 51 mg (0.2 mmol) 12 was dissolved in 1 mL THF and added dropwise. Then the vessel was fitted with a condenser and the reaction mixture was refluxed under N2 for 5 hrs. Excess NaBH4 was quenched with methanol. After removal of solvent, 2 mL water and 5 mL methylene chloride was added, the mixture was stirred for about 1 hr until the organic layer became clear.
The organic phase was collected and aqueous phase was further extracted twice with methylene chloride. The combined organic extraction was dried and concentrated to provide 43 mg (71 Io) of the crude product. Further purification on TLC with methanol/chloroform (5:95) provided 13 mg of clear oil. J. Org. Chem., 1993, 58, 3568-3571. 'H NMR (CD3OD) S 7.11 (m, 4H, ArH), 3.80 (t, J=7.5Hz, 1 H, c-pentyl-CH2O), 3.67 (t, J=7.5Hz, 1 H, c-pentyl-CH2O), 3.01 (m, 1 H, ArCHCC), 2.55 (t, T 7.5Hz, 2H, ArCH2), 2.29-1.69 (m, 6H, cyclo-pentyl); 1.57 (m; 2H, ArCHZCH ), 1.38-1.28 (m, IOH, CH2), 0.89 (t, J=7.5Hz, 3H, CH3); 13C NMR (CD3COCD3),S
141,.
128, 127, 96, 45, 44, 43, 35, 35; 33, 33, 32, 32, 29, 29, 19, 23, 13. ' Example 2: (1-amino-3-(4-octylphenyl)cyclopentyl)methyl dihydrogen phosphate (7) [00124] 1 mL of 85%*H3P04 was slowly added (by drops) into 0.5g of P205, the acid-anhydride mixture was then heated at 100 C for 1 hour under nitrogen protection. Another 0.5g of P205 and 30 mg of alcohol 6 were added to the poly phosphoric acid and.heated for 5 hours at 100 C. After cooling down to room temperature, 10 mL cold water (0 C) was added to reaction mixture. The product precipitated out as white solid, was collected and washed with water. 31 mg (82%) of green colored product was collected after vacuum drying. MS only two peaks:
M+1=384.4 with 304.4 (hydrolyzed back to 6).
Examnle 3: Separation of Isomers of VPC01091 [00125] The mixture of isomers of compound VPC01091 is preformed using a Chiralpak AD-H 4.6 mm ID x 250 mm column, at 45 C, solvent flow rate: 0.8 mL/min (isocratic), solvent: 95% heptane : 2.5% ethanol : 2.5% methanol (0.2%
diethylamine added as modifier to 95:2.5:2.5 mixture). The run time was 40 min, UVI, wavelength monitored: 254nm. The order of isomer elution was D, C, B, and A.
Example 4: Pain Assay [00126] Test compound, VPC01091 (Drug T, mixture of all isomers), was dissolved in 2% hydroxypropyl beta-cyclodextrin in water and administered to the test group of laboratory rats. The vehicle (Drug V: 2% hydroxypropyl beta-cyclodextrin in water) was administered to the control group of laboratory rats. Each group included 11 animals.
[00127] The identities of 'Drug T' an'd `Drug V' were maintained iry secret to, prevent bias. The test solutions (test compound or vehicle) were intraperitoneally (IP) administered once (day 0), the dose was 10 mg/kg body weight. On day Q, each of the 22 animals was anesthetized, the sciatic nerve bundle on the right side exposed surgically, and crushed mechanically. This is known as the `trauma' model of neuropathic pain. The animals were tested each day for the time required to lift either paw after illumination with small heat lamp. Normal PWL (paw withdrawal latency) time in an adult rat is 10-11 seconds, an untreated rat with a crushed sciatic nerve exhibits thermal hyperalgesia having a PWL time decreases to about 6 seconds.
[00128] Treatment of the animals with VPC01091 (Drug T) prevented the development of thermal hyperalgesia in the affected (crushed nerve) paw, and exhibited an analgesic effect, due to PWL time increases after injury, only on the affected side. The results are illustrated in Figs. 2 and 3.
[00129] Other, non-S1P receptor active, compounds that prevent thermal (or mechanical) allodynia from developing in such models are known. Likewise, drugs that cause general analgesia (e.g., morphine) are known.
Example 5: Analgesic Effects of VPC01091-D
[00130] The compound VPC01091-D was demonstrated to be effective at blocking mechanical allodynia associated with nerve injury in two preclinical models of neuropathic pain, sciatic nerve injury (CCI) and spinal nerve injury (SNL) models using groups of rats (7). In these models, oral treatment with VPC01091-D was started 2 weeks following nerve injury, once the pain was established. A
control group received only vehicle. Following once a day dosing for 5 days, VPC01091-D
(3mg/kg, p.o.) reversed mechanical allodynia by 42 8% in the CCI model. (See Figure 5).
[00131] VPC01091-D (3 mg/kg, p.o.) produced similar analgesic activity (50 10%) in the SNL model. Oral duloxetine, a drug approved for the treatment of neuropathic pain, produces a similar degree of analgesic efficacy in both models at a dose of 30 mg/kg, p.o.
[00132] All references cited herein are expressly incbrporated herein by reference in their entirety into this disclosure. Illustrative embodiments of this disclosure are discussed and refeirence has been made to possible variations within the scope of this disclosi.ure. These and other variations and modifications in the disclosure will be apparent to those skilled in the art without departing from the scope of the disclosure, and it should be understood that this disclosure and the claims shown below are not limited to the illustrative embodiments set forth herein.
Claims (20)
1. A method for prevention or treatment of neuropathic pain in a mammal, comprising administering to said mammal an effective amount of a compound having the formula:
wherein R4 and R7 are independently CH, or CH2; R5 is C, CH, or N, R6 is CH, CH2, O, S or NR3; wherein R3 is hydrogen, or an (C1-C10) alkyl group;
X is selected from hydroxyl, phosphate, phosphonate, alpha-substituted phosphonate;
R1 is selected from the group consisting of hydrogen, halo, tri-fluoromethyl, (C1-C10) alkyl, (C1-C10) alkyl substituted with halo, hydroxy-, (C1-C10) alkoxy, or cyano; and R2 is selected from the group consisting of (C1-C20)alkyl, cycloalkyl substituted alkyl, (C2-C20)alkenyl, (C2-C20)alkynyl, aryl, alkyl substituted aryl, arylalkyl and aryl substituted arylalkyl; wherein one or more of the carbon atoms in the R2 groups can be independently replaced with non-peroxide oxygen, sulfur or NR8; wherein R8 is hydrogen, or an (C1-C10) alkyl group;
wherein the alkyl, alkenyl, and alkynyl groups in R2 are optionally substituted with oxo; n is 0, 1, 2 or 3; and represents 1, 2, or 3, optional double bonds; or a pharmaceutically acceptable salt or ester thereof.
wherein R4 and R7 are independently CH, or CH2; R5 is C, CH, or N, R6 is CH, CH2, O, S or NR3; wherein R3 is hydrogen, or an (C1-C10) alkyl group;
X is selected from hydroxyl, phosphate, phosphonate, alpha-substituted phosphonate;
R1 is selected from the group consisting of hydrogen, halo, tri-fluoromethyl, (C1-C10) alkyl, (C1-C10) alkyl substituted with halo, hydroxy-, (C1-C10) alkoxy, or cyano; and R2 is selected from the group consisting of (C1-C20)alkyl, cycloalkyl substituted alkyl, (C2-C20)alkenyl, (C2-C20)alkynyl, aryl, alkyl substituted aryl, arylalkyl and aryl substituted arylalkyl; wherein one or more of the carbon atoms in the R2 groups can be independently replaced with non-peroxide oxygen, sulfur or NR8; wherein R8 is hydrogen, or an (C1-C10) alkyl group;
wherein the alkyl, alkenyl, and alkynyl groups in R2 are optionally substituted with oxo; n is 0, 1, 2 or 3; and represents 1, 2, or 3, optional double bonds; or a pharmaceutically acceptable salt or ester thereof.
2. The method of claim 1, wherein the compound has Formula (IIA):
wherein X is selected from hydroxyl, phosphate, phosphonate, and alpha-substituted phosphonate;
wherein R1 is selected from the group consisting of hydrogen, halogens, (C1-C6) alkyl, and halo-, hydroxy-, alkoxy-, cyano-substituted (C1-C6) alkyl;
R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkyl substituted aryl, alkyl substituted cycloalkyl, arylalkyl and arylalkyl substituted aryl; and n is 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
wherein X is selected from hydroxyl, phosphate, phosphonate, and alpha-substituted phosphonate;
wherein R1 is selected from the group consisting of hydrogen, halogens, (C1-C6) alkyl, and halo-, hydroxy-, alkoxy-, cyano-substituted (C1-C6) alkyl;
R2 is selected from the group consisting of alkyl, alkenyl, alkynyl, alkyl substituted aryl, alkyl substituted cycloalkyl, arylalkyl and arylalkyl substituted aryl; and n is 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
3. The method of claims 1 or 2, wherein R1 is fluorine or chlorine.
4. The method of any of claims 1-3, wherein X is hydroxy or OPO3H2.
5. The method of claim 4, wherein X is OPO3H2.
6. The method of claim 4, wherein X is hydroxy.
7. The method of claims 1 or 2, wherein the alpha-substituted phosphonate is -CHFPO3H2, -CF2PO3H2, -CHOHPO3H2, -C=OPO3H2 or -OPO2SH2.
8. The method of claim 7, wherein the alpha-substituted phosphonate is -CHFPO3H2, -CF2PO3H2, -CHOHPO3H2, or -C=OPO3H2.
9. The method of any of claims 1-8, wherein R1 is hydrogen.
10. The method of any of claims 1-9, wherein R2 is alkyl having 5, 6, 7, or 8 carbon atoms.
11. The method of claim 10, wherein R2 is heptyl, octyl, nonyl, or -O-heptyl.
12. The method of claim 11, wherein R2 is n-octyl.
13. The method of any of claims 1-12, wherein n is 1 or 2.
14. The method of claim 13, wherein n is 2.
15. The method of any of claims 1-14, wherein the R2 group is placed para to the cycloalkyl ring.
16. The method of any of claims 1-15, wherein the cycloalkyl group has the formula:
17. The method of any of claims 1-16, wherein the R1 group is ortho or meta to R2.
18. The method of any of claims 1-16, wherein the R2 group is para to the benzylic cycloalkyl group.
19. The method of claims 1 or 2, wherein the compound has the formula:
20. The method of claim 19, wherein the compound has the formula:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76258906P | 2006-01-27 | 2006-01-27 | |
US60/762,589 | 2006-01-27 | ||
PCT/US2007/002422 WO2007089715A2 (en) | 2006-01-27 | 2007-01-29 | Method for treatment of neuropathic pain |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2640366A1 true CA2640366A1 (en) | 2007-08-09 |
Family
ID=38179799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002640366A Abandoned CA2640366A1 (en) | 2006-01-27 | 2007-01-29 | Method for treatment of neuropathic pain |
Country Status (13)
Country | Link |
---|---|
US (1) | US8008286B2 (en) |
EP (1) | EP1986623A2 (en) |
JP (1) | JP2009528274A (en) |
KR (1) | KR20080086546A (en) |
CN (1) | CN101378741A (en) |
AU (1) | AU2007209961A1 (en) |
BR (1) | BRPI0707281A2 (en) |
CA (1) | CA2640366A1 (en) |
IL (1) | IL193040A0 (en) |
MX (1) | MX2008009579A (en) |
RU (1) | RU2008134702A (en) |
WO (1) | WO2007089715A2 (en) |
ZA (1) | ZA200806349B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1827606A2 (en) | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
JP2009526073A (en) * | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | Bicyclic sphingosine-1-phosphate receptor analogs |
JP2010510249A (en) | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | Sphingosine = 1-tetralin analog having 1-phosphate agonist activity |
EP2099741A2 (en) | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
EP2097371A2 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
MX2009006748A (en) | 2006-12-21 | 2009-06-30 | Abbott Lab | Process for the preparation and isolation of the individual stereoisomers of 1-amino, 3-substituted phenylcyclopentane carboxylates. |
EP2177521A1 (en) | 2008-10-14 | 2010-04-21 | Almirall, S.A. | New 2-Amidothiadiazole Derivatives |
EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
EP2343287A1 (en) | 2009-12-10 | 2011-07-13 | Almirall, S.A. | New 2-aminothiadiazole derivatives |
EP2366702A1 (en) | 2010-03-18 | 2011-09-21 | Almirall, S.A. | New oxadiazole derivatives |
EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
WO2012129073A2 (en) * | 2011-03-18 | 2012-09-27 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
US9115054B2 (en) | 2013-02-21 | 2015-08-25 | Bristol-Myers Squibb Company | Tetrahydronaphthalenyl compounds useful as sipi agonists |
MA40082B1 (en) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | New Sphingosine Phosphate Substitution Compound Useful Treatment Disease Rheumatism |
KR20210058568A (en) * | 2019-11-14 | 2021-05-24 | 삼성전자주식회사 | Resistive memory device controlling bitline voltage |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1056139B (en) | 1956-03-31 | 1959-04-30 | Hoechst Ag | Process for the preparation of alpha-amino-beta-oxy-carboxylic acid anilides |
US3153092A (en) * | 1961-07-17 | 1964-10-13 | Smith Kline French Lab | 1-methyl-2-phenylcyclopropylamine derivatives |
DE3544373A1 (en) | 1985-12-14 | 1987-06-19 | Hoechst Ag | Process for the preparation of phosphinothricin-carboxamides |
EP0275821B1 (en) * | 1986-11-21 | 1992-02-26 | Ciba-Geigy Ag | Substituted alkanediphosphonic acids |
US5656762A (en) * | 1990-12-28 | 1997-08-12 | Neurogen Corporation | 4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands |
DE4134156A1 (en) * | 1991-10-11 | 1993-04-15 | Schering Ag | 9-SUBSTITUTED BICYCLO (3.3.0) OCTANE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL USE |
JPH06135935A (en) | 1992-10-24 | 1994-05-17 | Fuji Kagaku Kogyo Kk | New naphthalene derivative and its intermediate |
JPH06135936A (en) | 1992-10-24 | 1994-05-17 | Fuji Kagaku Kogyo Kk | New naphthalene derivative and its intermediate |
JP2002500041A (en) * | 1997-12-30 | 2002-01-08 | エヌピーエス アレリックス コーポレーション | Identification of lysolipid receptor involved in inflammatory response |
PT1258484E (en) | 2000-02-18 | 2009-04-03 | Kyowa Hakko Kirin Co Ltd | Novel isoxazole and thiazole compounds and use thereof as drugs |
KR100874392B1 (en) | 2000-03-17 | 2008-12-17 | 유니버시티 오브 테네시 리서치 파운데이션 | LPA agonists and antagonists, and methods of use |
US6814319B2 (en) * | 2000-12-06 | 2004-11-09 | Pharmacia & Upjohn Company | Laboratory scale milling process |
AU2002237988B2 (en) * | 2001-01-30 | 2008-01-03 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
MXPA03008755A (en) | 2001-03-26 | 2004-02-18 | Novartis Ag | 2-amino-propanol derivatives. |
JP2002316985A (en) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | Benzothiophene derivative |
DE60230262D1 (en) | 2001-05-10 | 2009-01-22 | Ono Pharmaceutical Co | CARBOXYLENE DERIVATIVES AND THESE DRUGS CONTAINING ACTIVE SUBSTANCE |
PL211954B1 (en) | 2002-01-11 | 2012-07-31 | Sankyo Co | Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
CA2472680A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
US7241790B2 (en) * | 2002-07-30 | 2007-07-10 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
WO2004017917A2 (en) | 2002-08-26 | 2004-03-04 | Merck & Co., Inc. | Method for the prevention and/or treatment of atherosclerosis |
EP1539674A1 (en) | 2002-09-13 | 2005-06-15 | Novartis AG | Amino-propanol derivatives |
MXPA05003254A (en) | 2002-09-24 | 2005-06-08 | Novartis Ag | Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders. |
EP1581510A4 (en) | 2002-11-22 | 2006-08-30 | Bristol Myers Squibb Co | 1-aryl-2-hydroxyethyl amides as potassium channel openers |
WO2004074297A1 (en) | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonic acid derivatives, addition salts thereof and s1p receptor modulators |
WO2004089918A1 (en) * | 2003-04-09 | 2004-10-21 | Japan Tobacco Inc. | Heteroaromatic pentacyclic compound and medicinal use thereof |
JP2004307442A (en) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | Heterocyclic derivative, its addition salt and immunosuppressant |
WO2004096757A1 (en) | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
BRPI0410025A (en) | 2003-04-30 | 2006-04-25 | Novartis Ag | amino-propanol derivatives as sphingosine-1-phosphate receptor modulator |
CN1788008A (en) | 2003-05-15 | 2006-06-14 | 麦克公司 | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
ES2379169T3 (en) * | 2003-05-19 | 2012-04-23 | Irm Llc | Immunosuppressive compounds and compositions |
EP1481680A1 (en) * | 2003-05-30 | 2004-12-01 | Aventis Pharma Deutschland GmbH | Use of S1P |
CA2539438A1 (en) | 2003-10-01 | 2005-04-14 | Merck And Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
US7638637B2 (en) * | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
GB0411929D0 (en) | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
JP5315611B2 (en) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Compound having S1P receptor binding ability and use thereof |
US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
BRPI0514316A (en) * | 2004-08-13 | 2008-06-10 | Praecis Pharm Inc | methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
EP1827606A2 (en) * | 2004-12-06 | 2007-09-05 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
KR20070104407A (en) * | 2005-02-14 | 2007-10-25 | 유니버시티 오브 버지니아 페이턴트 파운데이션 | Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substitued by amino and phenyl groups |
DE602007003074D1 (en) | 2006-01-24 | 2009-12-17 | Actelion Pharmaceuticals Ltd | NEW PYRINE DERIVATIVES |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
TW200806611A (en) | 2006-02-09 | 2008-02-01 | Daiichi Seiyaku Co | Novel amidopropionic acid derivatives and medicine containing the same |
JP2009526073A (en) * | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | Bicyclic sphingosine-1-phosphate receptor analogs |
CN101460458A (en) * | 2006-02-15 | 2009-06-17 | 阿勒根公司 | Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
AU2007217006A1 (en) * | 2006-02-21 | 2007-08-30 | University Of Virginia Patent Foundation | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists |
EP2099741A2 (en) | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
JP2010510249A (en) | 2006-11-21 | 2010-04-02 | ユニバーシティ オブ バージニア パテント ファンデーション | Sphingosine = 1-tetralin analog having 1-phosphate agonist activity |
EP2097371A2 (en) | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
AU2007338700A1 (en) * | 2006-12-21 | 2008-07-03 | Abbott Laboratories | Sphingosine-1 -phosphate receptor agonist and antagonist compounds |
AU2008286770A1 (en) | 2007-08-15 | 2009-02-19 | Biogen Idec Ma Inc. | Bicyclic sphingosine 1-phosphate analogs |
EP2203409A2 (en) | 2007-09-28 | 2010-07-07 | University Of Virginia Patent Foundation | Benzyl-cycloalkyl sphingosine 1-phosphate receptor modulators |
WO2009146112A1 (en) | 2008-04-02 | 2009-12-03 | University Of Virginia Patent Foundation | Compositions and methods for inhibiting sphingosine kinase |
-
2007
- 2007-01-29 BR BRPI0707281-3A patent/BRPI0707281A2/en not_active IP Right Cessation
- 2007-01-29 EP EP07717121A patent/EP1986623A2/en not_active Withdrawn
- 2007-01-29 WO PCT/US2007/002422 patent/WO2007089715A2/en active Application Filing
- 2007-01-29 MX MX2008009579A patent/MX2008009579A/en not_active Application Discontinuation
- 2007-01-29 JP JP2008552487A patent/JP2009528274A/en active Pending
- 2007-01-29 RU RU2008134702/04A patent/RU2008134702A/en not_active Application Discontinuation
- 2007-01-29 CN CNA2007800037540A patent/CN101378741A/en active Pending
- 2007-01-29 CA CA002640366A patent/CA2640366A1/en not_active Abandoned
- 2007-01-29 AU AU2007209961A patent/AU2007209961A1/en not_active Abandoned
- 2007-01-29 KR KR1020087020888A patent/KR20080086546A/en not_active Application Discontinuation
-
2008
- 2008-07-22 ZA ZA200806349A patent/ZA200806349B/en unknown
- 2008-07-24 IL IL193040A patent/IL193040A0/en unknown
- 2008-07-25 US US12/179,816 patent/US8008286B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009528274A (en) | 2009-08-06 |
CN101378741A (en) | 2009-03-04 |
IL193040A0 (en) | 2009-02-11 |
KR20080086546A (en) | 2008-09-25 |
ZA200806349B (en) | 2009-06-24 |
US20090062238A1 (en) | 2009-03-05 |
AU2007209961A1 (en) | 2007-08-09 |
US8008286B2 (en) | 2011-08-30 |
WO2007089715A3 (en) | 2007-09-27 |
RU2008134702A (en) | 2010-03-10 |
EP1986623A2 (en) | 2008-11-05 |
MX2008009579A (en) | 2008-09-25 |
BRPI0707281A2 (en) | 2011-04-26 |
WO2007089715A2 (en) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8008286B2 (en) | Method for treatment of neuropathic pain | |
AU2006214314B2 (en) | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups | |
CA2641661A1 (en) | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists | |
US20090042955A1 (en) | Bicyclic sphingosine 1-phosphate analogs | |
US7960588B2 (en) | Benzyl cycloalkyl sphingosine 1-phosphate receptor modulators | |
US8283339B2 (en) | Vinyl phosphonate lysophosphatidic acid receptor antagonists | |
EP2099741A2 (en) | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity | |
CA2669102A1 (en) | Tetralin analogs having sphingosine 1-phosphate agonist activity | |
AU2007323557A1 (en) | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity | |
NZ564130A (en) | N-propargyl-1-aminoindan compounds useful for treating obesity | |
AU2012202703A1 (en) | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups | |
MX2008010474A (en) | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as sip receptor agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |